TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
 
 
 
STUDY PROTOCOL  
 
 
 
A Phase 3, Multicenter , Expanded Access Study of Ibalizumab Plus an Optimized 
Background Regimen (OBR) in Treatment -Experienced Patients Infected With Multi -Drug 
Resistant (MDR) HIV -1 
 
PROTOCOL NUMBER: TMB -311 
[STUDY_ID_REMOVED]  
 
 
Version:  1.3 
Date of Protocol:  11 December   2017 
 
Sponsor:  TaiMed Biologics, Inc.  
2 Executive Circle , Suite 280  
Irvine, CA 92614  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  ii      
Sponsor Contact:  TaiMed Biologics, Inc.  
2 Executive Circle , Suite 280  
Irvine, CA 92614  
Project Manager:  
 Christine Anderson, PhD  
Westat  
1600 Research Blvd.  
Rockville, MD 20850  
Phone: 713-353-7911 
 
Primary Contact:  Stanley Lewis, MD  MPH  
Vice-President and Chief Medical Officer  
2 Executive Circle , Suite 280  
Irvine, CA 92614  
Phone: 713 -252-2619 
Medical Monitor:  Stanley Lewis, MD  MPH  
Vice-President and Chief Medical Officer  
2 Executive Circle , Suite 280  
Irvine, CA 92614  
Phone: 713 -252-2619 
Serious Adverse 
Event Reporting:  Westat  
1600 Research Blvd.  
Rockville, MD 20850  
Phone: 888 -464-5246 
Fax: 888 -865-1983 
Email: Regulatory@Westat.com  
 
Proprietary Notice:  This document contains mainly unpublished data and is the sole 
property of TaiMed Biologics , Inc. Therefore, it is provided to you in 
strict confidence as an investigator, potential investigator, or consultant. 
The information may be reviewed by you, your staff, and your 
institutional review board/independent ethics committee. It is 
understood that this information will not be disclosed to others without 
written authorization from TaiMed Biologics , Inc., except to the extent 
necessary to obtain informed con sent from those persons to whom the 
drug may be administered.  
 
Ethics Statement : The study will be completed according to the International Conference 
on Harmonisation guideline s E6(R1): Good Clinical Practice: 
Consolidated Guideline  and E2A: Clinical Saf ety Data Management . 
Compliance with this standard provides public assurance that the rights, 
safety, and well -being of trial patient s are protected, consistent with the 
principles that have their origin in the Declaration of Helsinki. The 
study will also follow the standards set forth in the Code of Federal 
Regulations Title 21 Parts 11 (Electronic Records), 50 (Protection of 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  iii    Human Subjects), 54 (Financial Disclosure by Clinical Investigators), 56 
(Institutional Review Boards ), and 312 (Investigational New  Drug 
Application ).  
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  iv    Table of Contents  
 
 
PROTOCOL SUMMARY  ................................ ................................ ................................ ..... 1 
ABBREVIATIONS  ................................ ................................ ................................ .................  7 
1. Introduction  ................................ ................................ ................................ ..........................  9 
1.1 Background  ................................ ................................ ............................  9 
1.2 Clinical Studies  ................................ ................................ ......................  9 
1.3 Pharmacokinetic Profile  ................................ ................................ .... 15 
2. Study Objectives  ................................ ................................ ................................ .................  16 
2.1 Primary Objectives  ................................ ................................ .............  16 
2.2 Secondary Objectives  ................................ ................................ .........  16 
3. Study Plan  ................................ ................................ ................................ ............................  17 
3.1 Overall Design  ................................ ................................ ....................  17 
3.2 Discussion of Trial Design  ................................ ...............................  18 
3.3 Dose Selection  ................................ ................................ ....................  19 
3.4 Schedule of Events  ................................ ................................ .............  19 
3.5 Effectiveness Assessments ................................ ................................  44 
3.6 Safety Assessments  ................................ ................................ .............  44 
4. Stu dy Treatments  ................................ ................................ ................................ ...............  45 
4.1 Study Drug Dosage and Administration  ................................ ........ 45 
4.1.1  Cohort 1  ................................ ................................ ..............  45 
4.1.2  Cohort 2  ................................ ................................ ..............  46 
4.1.3  Administration  ................................ ................................ .... 47 
4.2 Prohibited Medications and Restrictions ................................ ........ 47 
4.3 Measurement of Patient Adherence  ................................ ................  49 
4.4 Missed Doses of Study Drug  ................................ ............................  49 
4.4.1  Cohort 1  ................................ ................................ ..............  49 
4.4.2  Cohort 2  ................................ ................................ ..............  50 
4.5 Study Drug Description  ................................ ................................ .... 51 
4.6 Study Drug Packaging, Storage, and Disposal  ...............................  51 
4.7 Study Drug Accountability ................................ ................................  52 
5. Patient Enrollment  ................................ ................................ ................................ .............  53 
5.1 Inclusion Criteria  ................................ ................................ ................  53 
5.2 Exclusion Criteria  ................................ ................................ ...............  54 
5.3 Patient Withdrawal and Discontinuation  ................................ ....... 56 
5.3.1  Reasons for Withdrawal  ................................ ....................  56 
5.3.2  Handling Withdrawals and Discontinuations  ...............  57 
5.3.3  Sponsor or Regulatory Agency Termination of 
Study  ................................ ................................ .....................  57 
6. Study Visits  ................................ ................................ ................................ ..........................  58 
6.1 Cohort 1: 800 mg Every 2 Weeks  ................................ ....................  58 
6.1.1  Screening/Day 0  ................................ ................................  58 
6.1.2  Events for Day 14 (±1 day) and Weeks 4, 6, 8, 
10, 14, 16, 18, 20, 22, 26, 28, 30, 32, 34, 38, 40, 
42, 44, 46, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  v    74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 98, 100, 
102, 104, 106, 110, 112, 114, 116, 118, 122, 124, 
126, 128, 130, 134, 136, 138, 140, and 142 (±2 
days) ................................ ................................ ......................  60 
6.1.3  Events for Weeks 12, 24, 36, 48, 60, 72, 96, 108, 
120, 132, 144/EOS and 150/Follow -up (±2 
days) ................................ ................................ ......................  60 
6.2 Cohort 1: 2,000 mg Every 4 Weeks ................................ .................  61 
6.2.1  Screening/Day 0  ................................ ................................  62 
6.2.2  Events for Weeks 4, 8, 16, 20, 28, 32, 40, 44, 52, 
56, 64, 68, 76, 80, 84, 88, 92, 100, 104, 112, 116, 
124, 128, 136, and 140 (±2 days) ................................ ..... 64 
6.2.3  Events for Weeks 12, 24, 36, 48, 60, 72, 96, 108, 
120, 132, , 144/EOS, and 150/Follow -up (±2 
days) ................................ ................................ ......................  64 
6.3 Cohort 2  ................................ ................................ ...............................  65 
6.3.1  Screening (Weeks -6 to -1) ................................ ...............  66 
6.3.2  Day 0/Baseline  ................................ ................................ ... 67 
6.3.3  Events for Day 7 (±1 day)  ................................ ...............  68 
6.3.4  Events for Day 14 (±1 day), and Weeks 4, 6, 8, 
10, 14, 16, 18, 20, 22, 26, 30, 32, 34, 38, 40, 42, 
44, 46, 50, 52, 54, 56, 58, 62, 64, 66, 68, 70, 74, 
76, 78, 80, 82, 86, 88, 90, 92, 94, 98, 100, 102, 
104, 106, 110, 112, 114, 116, 118, 122, 124, 126, 
128, 130, 134, 136, 138, 140, and 142 (±2 days) ...........  69 
6.3.5  Events for Weeks 12, 24, 48, 60, 72, 84, 96, 108, 
120, 132, and 144/EOS (±2 days)  ................................ .. 70 
6.3.6  Events for Weeks 28 and 36 (±2 days)  ..........................  71 
6.3.7  Events for Week 150/Follow -up Visit (±2 days) 
(Study drug is not administered at this visit)  .................  71 
6.4 Early Withdrawal Procedures  ................................ ...........................  72 
6.5 Unscheduled Visits  ................................ ................................ .............  73 
7. Study Assessments  ................................ ................................ ................................ .............  74 
7.1 Activities to Be Completed  ................................ ...............................  74 
7.1.1  Demographic Data, Medical History, and 
Concomitant Medications  ................................ ................  74 
7.1.2  Complete Physical Examination  ................................ ..... 74 
7.1.3  Abbreviated Physical Examination  ................................ . 75 
7.1.4  Vital Sign Measurements  ................................ ..................  75 
7.2 Blood and Urine Samples  ................................ ................................ .. 75 
7.2.1  Hepatitis Serology and C -Reactive Protein  ...................  75 
7.2.2  Clinical Laboratory Parameters  ................................ ....... 75 
7.2.3  Archive Sample  ................................ ................................ .. 76 
7.2.4  Serum Follicle -Stimulating Hormone Testing  ..............  77 
7.2.5  Pregnancy Testing  ................................ ..............................  77 
7.2.6  HIV-1 RNA Level  ................................ .............................  77 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  vi    7.2.7  HIV-1 Viral Resistance Testing  ................................ ....... 77 
7.2.8  CD4+ Cell Count  ................................ ................................  78 
7.2.9  Immunogenicity of Ibalizumab  ................................ ....... 78 
8. Adverse Events  ................................ ................................ ................................ ...................  78 
8.1 Defini tions  ................................ ................................ ...........................  78 
8.2 Eliciting Adverse Event Information ................................ ..............  79 
8.3 Reporting Adverse Events  ................................ ................................  80 
8.4 Assessment of Causality  ................................ ................................ .... 81 
8.5 Assessment of Severity  ................................ ................................ ...... 82 
8.6 Serious Adverse Event Reporting  ................................ ...................  83 
8.7 Pregnancy  ................................ ................................ .............................  85 
9. Statistical Considerations  ................................ ................................ ................................ .. 87 
9.1 General Methodology  ................................ ................................ ........ 87 
9.2 Populations for Analysis ................................ ................................ .... 87 
9.2.1  Efficacy Populations ................................ ..........................  87 
9.2.2  Safety Population  ................................ ...............................  88 
9.3 Patient Disposition  ................................ ................................ .............  88 
9.4 Definition of Baseline  ................................ ................................ ........ 88 
9.5 Demographics and Baseline Characteristics  ................................ .. 89 
9.6 Exposure to Study Medication  ................................ .........................  89 
9.7 Safety Analyses  ................................ ................................ ....................  89 
9.7.1  Adverse Events  ................................ ................................ .. 89 
9.7.2  Clinical Safety Laboratory Parameters  ...........................  89 
9.8 Efficacy  ................................ ................................ ................................ . 90 
10. Data Handling and Quality Assurance  ................................ ................................ .........  90 
10.1  Electronic Case Report Forms  ................................ .........................  90 
10.2  Monitoring of the Study  ................................ ................................ .... 91 
10.3  Inspection of Records ................................ ................................ ........ 92 
10.4  Study Record Retention  ................................ ................................ .... 92 
11. Administrative Considerations  ................................ ................................ ......................  93 
11.1  Confidentiality  ................................ ................................ .....................  93 
11.2  Institutional Review Board or Independent Ethics 
Committee Approval  ................................ ................................ .........  93 
11.3  Modification of the Protocol  ................................ ............................  94 
11.4  Informed Consent  ................................ ................................ ..............  94 
11.5  Protocol Violations and Deviations  ................................ ................  95 
11.6  Study Reporting Requirements  ................................ ........................  96 
11.7  Financial Disclosure and Obligations  ................................ .............  96 
11.8  Investigator Documentation ................................ .............................  97 
11.9  Study Conduct  ................................ ................................ .....................  97 
11.10  Publications  ................................ ................................ .........................  98 
 Reference s ................................ ................................ ................................ ..........  99 
 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  vii    Appendi ces 
Appendi ces to this protocol are presented in a separate document titled:  
“Appendices to Protocol TMB -311: A Phase 3, S ingle Arm, Multicenter , Expanded Access  Study of 
Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment -Experienced Patients 
Infected With Multi -Drug Resistant (MDR) HIV-1” 
 
The Appendices include the following:  
 
Appendix A : CDC Classification System for HIV Infection  
Appendix B : Division of AIDS: Table for Grading the Severity of Adult and Pe diatric 
Adverse Events Version 2 .0, November 201 4 
Appendix C : “The diagnosis and management of anaphylaxis: An updated practice 
parameter”  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  1    PROTOCOL SUMMARY  
 
Protocol Number:  TMB -311 
Title:  A Phase 3, Multicenter , Expanded Access  Study of Ibalizumab Plus an 
Optimized Background Regimen (OBR) in Treatment -Experienced 
Patients Infected With Multi -Drug -Resistant (MDR) HIV-1  
Sponsor : TaiMed Biologics, Inc.  
2 Executive Circle, Suite 280  
Irvine, CA 92614  
Study Phase:  3 
Patients and 
Investigator Sites:  Anticipated enrollment is approximately 100 patients from 
approximately 40 sites in North America and the European Union ; 
however , the numbers of participating patients will not be limited and 
may exceed 100 and the number of sites will not be limited and may 
exceed 40. 
Study Drug Dosage 
and Route of 
Administration:  The investigational product, ibalizumab , is a humanized IgG4 
monoclonal antibody (MAb) administered via intravenous infusion  (IV). 
Patients will be enrolled in one of two Cohorts (Cohort 1 and Cohort 
2). Cohort 1 patients will continue their current dosage of ibalizumab 
(800 mg every 2 weeks or 2,000  mg every 4 wee ks). Cohort 2 patients 
will rec eive a 2,000  mg loading dose at Baseline /Day 0  followed by 800 
mg maintenance doses every 2 weeks.  
All patients will receive an OBR, which is a standard -of-care regimen 
selected by the investigator based on treatment history and the results of 
viral resistance testing.  
Control Drug, Dosage, 
and Rout e of 
Administration:  None  
Objectives:  
 The primary objective s of this study are to: 
 
Cohort 1  
◼ Continue to provide ibalizumab to patients currently receiving 
ibalizumab treatment under Investigator -sponsored INDs  or 
TaiMed -sponsored protocols  
◼ Demonstrate the safety and tolerability of ibalizumab  in human 
immunodeficiency virus ( HIV)-positive patients with MDR HIV 
infection  
Cohort 2  
◼ Provide access to ibalizumab for qualifying MDR HIV -1-infected 
patients with limite d treatment options  
◼ Demonstrate the safety and tolerability of ibalizumab  in HIV -
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  2    positive patients with MDR  HIV infection  
The secondary objectives of this study are to:  
 
◼ Demonstrate the antiviral activity of ibalizumab in HIV -positive 
patients with MDR  HIV infection  
◼ Characterize  HIV-1 sensitivity/susceptibility changes associated 
with protocol -defined virologic failure after ibalizumab  
administration in  combination with the OBR  
◼ Determine the presence and significance of anti -ibalizumab  
antibodies  associated with protocol -defined virologic failure after 
ibalizumab administration , if any (immunogenicity of ibalizumab ) 
Patient Population : 
Inclusion  Criteria  
 Patients will be enrolled in one of two Cohorts  (Cohort 1 and    Cohort 
2)   
 
Patients may be enrolled in Cohort 1  if they meet both of the following 
criteria : 
 
1. Are currently receiving ibalizumab via other TaiMed -sponsored  or 
Investigator -sponsored IND protocol  
2. Are cap able of understanding and have voluntarily signed the 
informed consent document  
 
Patients may be enrolled in Cohort 2  if they meet all of the following 
criteria:  
 
1. Are 18 years of age or older  
2. Are capable of understanding and have voluntarily signed the 
informed consent document  
3. Have documented HIV -1 infection by official, signed, written 
history (e.g., laboratory report) ; otherwise , an HIV -antibody test will 
be performed  
4. Are able and willing to comply with all protocol requirements and 
procedures  
5. Have a viral load >1 ,000 copies/mL and documented resistance to 
at least one antiretroviral medication from each of three classes of 
antiretroviral medications as measured by previous viral resistance 
testing  (resistance testing is not provided by the study for 
qualification purposes)  
6. Have a history of at least 6 months on antiretroviral treatment  
7. Are receiving a failing  antiretroviral regim en OR have failed and are 
off therapy  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  3    8. Have viral sensitivity/susceptibility to at least one antiretroviral 
agent other than ibalizumab , as determined by a previous  resistance 
test performed within 6 months of Screening , and be willing and 
able to be treated with at least one agent to which the patient’s viral 
isolate is fully sensitive/susceptible according to the Screening 
resistance tests as a component of the OBR  
9. If sexually active, are willing to use an effective method of 
contraception during the study and for 30 days after the last 
administration of the study drug  
Patie nt Population : 
Exclusion Criteria  
 There are no Exclusion Criteria for patients meeting the Inclusion 
Criteria for Cohort 1.  
 
For Cohort 2 , patients  having or meeting any of the following 
conditions or characteristics will be excluded from the study:  
 
1. Eligible for participation in other TaiMed Biologics -sponsored 
clinical trials  of ibalizumab  
2. Any significant diseases (other than HIV -1 infection) or clinically 
significant findings, including psychiatric and behavioral problems, 
determined from Screening,  medical history , and/or physical 
examination that, in the investigator’s opinion, would preclude the 
patient from participating in th e study  
3. Any significant acute illness within 1 week before the first 
administration of investigational medication  on th e study 
4. Any active infection secondary to HIV requiring acute therapy; 
however, patients who require maintenance therapy (i.e., secondary 
prophylaxis for opportunistic infections) will be eligible for the 
study.  
5. Any immunomodulating therapy (including interferon), systemic 
steroids, or systemic chemotherapy within 4 weeks before Day 0  
6. Any prior e xposure to ibalizumab  (formerly TNX -355 and Hu5A8)  
7. Any vaccination within 7 days before Day 0 
8. Any female patient who is pregnant, intends to become p regnant, or 
is currently breast feeding  
9. Any current alcohol or illicit drug use that, in the investigator’s 
opinion, will interfere with the patient’s ability to comply with the 
study schedule and protocol evaluations  
10. Any previous clinically significant allergy or hypersensitivity to any 
excipient in the ibalizumab  formulation  
11. Any radiation therapy during the 28  days before first administration 
of investigational medication  on this study  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  4    12. Any clinically significant Grade 3 or 4 laboratory abnormality  
according to the Division of AIDS (DAIDS) grading scale, except 
for the  following asymptomatic G rade 3 events:  
➢ triglyceride elevation  
➢ total cholesterol elevation  
Study Design:  
 This Phase 3, multicenter , expanded access study will evaluate the safety 
and tolerability  of ibalizumab  in treatment -experienced patients infected 
with MDR  HIV-1. Patients will be enrolled in one of two Cohorts 
(Cohort 1 and Cohort 2):  
Cohort 1 (continuing treatment)  
◼ Patients will continue on an ibalizumab -containing regimen at 
their current dosage in combi nation with a current OBR.    
Cohort 2 (initiating ibalizumab ) 
◼ On Day 0 patients will receive one 2,000  mg dose (loading dose) 
of ibalizumab. An OBR  that is selected based on resistance test 
results and antiretroviral history will be initiated  on Day 0 and 
must include at least one agent to which the patient’s virus is 
susceptible.  
◼ Beginning at Day 1 4, 800 mg of ibalizumab  will be administered 
every 2 weeks through the remainder of the study . 
Virologic failure is defined as two consecutive measurements beginning 
at Week 24 or later if less tha n a 0.5 log 10 decline  in viral load  from 
Baseline viral load.  
Patients may be discontinued from the study : 
▪ At the patient’s  or investigator’s  request  
▪ If the patient becomes pregnant  
▪ For prot ocol violation  
▪ For experiencing virologic failure  
▪ For treatment -related serious or intolerable adverse events ( AEs) 
(DAIDS criteria, see Appendix B)  
▪ For toxicity (defined as two consecutive laboratory results, at 
least 14 days apart, with a CD4+ cell count  below 200 cells/mm3 
that also represents a 50% reduction from the baseline CD4+ 
cell count)  
▪ Upon commercial availability of ibalizumab  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  5    Safety and 
Effectiveness 
Assessments:  Primary safety and effectiveness variable s: 
 
Cohort 1 and Cohort 2  
◼ Safety and tolerability of ibalizumab  as assessed by AE s and 
Discontinuations  
 
Cohort 2 only  
◼ Proportion of patients achieving a ≥0.5 log 10 decrease from 
Baseline  in viral load at  Day 7 
 
Secondary safety and effectiveness variables:  
 
Cohort 1 and Cohort 2  
◼ HIV-1 sensitivity/susceptibility changes associated with virologic 
failure after administration of ibalizumab  
 
Cohort 2 only  
◼ Proportion of patients with HIV -1 RNA levels <50 copies/mL 
and <400 copies/mL at assessment time points  
◼ Mean change from Baseline  in viral load at Day 7 and all 
assessment time points  
◼ Proportion of patients achieving a ≥0.5 log 10 and ≥1.0 log 10 
decrease from Baseline  in viral load at all assessment time points  
 
Safety Assessments:  Safety assessments will include the following:  
◼ Physical examinations  
◼ Vital sign measurements  
◼ Clinical laboratory parameters (hematology, serum chemistry, and 
urinalysis)  
◼ Monitoring of AEs and concomitant medications  
◼ Incidence of Class C events as defined by the CDC  Classification 
System for HIV Infection  (Appendix A)  
◼ Anti-ibalizumab  antibody levels (immunogenicity of ibalizumab )  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  6    Statistical 
Considerations:  Sample Size : A sample size of approximately 100 patients is anticipated 
to be enrolled , though the number of participating patients will not be 
limited and may exceed 100. The analysis of study data will be primarily 
descriptive, with emphasis on tabular and graphical displays.  Summary 
descriptive statistics will be calculated along with po int and interval 
estimates of AEs.  
Effectiveness:  (Cohort 2 only) The primary effectiveness endpoint of 
the study is the proportion of patients achieving a ≥0.5 log 10 decrease 
from Baseline  in viral load at Day 7. 
Safety Analyses:  The safety analyses will include descriptions of 
treatment -emergent AEs (TEAEs) , Class C events per the CDC 
Classification System for HIV Infection, clinical laboratory test results, 
physical examination findings, vital sign results, and immunogenicity of  
ibalizumab . 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  7    ABBREVIATIONS  
 
ABBREVIATION  TERM  
  
AE adverse event  
AIDS  acquired immunodeficiency syndrome  
ALT alanine aminotransferase  
ART antiretroviral therapy  
AST aspartate aminotransferase  
CD4 glycoprotein expressed on the surface of T -helper cells  
CD4+ type of white blood cell, also called T -lymphocytes, T -cells, or T -helper cells  
CDC Centers for Disease Control and Prevention  
CFR Code of Federal Regulations  
cGMP  current Good Manufacturing Practices  
CRF case report form 
CT computed tomography  
DAIDS  Division of AIDS  
DSMB  data and s afety monitoring board  
EC ethics committee  
EDC electronic data capture  
ELISA  enzyme -linked immunosorbent assay  
EOS end of study  
FDA Food and Drug Administration  
FSH follicle -stimulating hormone  
HAART  highly active antiretroviral therapy  
HHS Department of Health and Human Services  
HIV-1 human immunodeficiency virus type -1 
HTE heterogeneous treatment effect  
ICH International Conference on Harmonisation  
ID identification  
IND Investigational New Drug  
IRB institutional review board  
ITT intent ion-to-treat  
IV intravenous  
LLOQ  lower limit of quantitation  
MAb  monoclonal antibody  
MDR  
MEdDRA  multi-drug resistant  
Medical Dictionary for Regulatory Activities  
MEF missing equals failure  
MESF  molecules of equivalent soluble fluorescence  
mITT  modified intention -to-treat 
Mu5A8  murine progenitor of ibalizumab  
OBR  optimized background regimen  
PK pharmacokinetics  
q2wk  every 2 weeks  
q4wk  every 4 weeks  
QOL quality of life 
RNA  ribonucleic acid  
SAE serious adverse event  
SAF safety dataset for analysis  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  8    ABBREVIATION  TERM  
SD standard deviation  
TEAE  treatment -emergent adverse event 
TFDA  Taiwan Food and Drug Administration  
US United States  
USP United States Pharmacopoeia  
WHODD  WHO Drug Dictionary  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  9    1. Introduction  
 
1.1 Background  
Antiretroviral medications for treatment of human immunodeficiency virus ( HIV) have evolved 
tremendously over recent years. Efficacy and tolerability have improved as well as the convenience 
of treatment regimens . The percentage of patients on treatment who maintain viral suppression 
approaches 75% -80%.1,2 Unfortunately, some pati ents harbor strains of HIV that are resistant to 
currently available therapies. Patients with multi -drug resistant ( MDR ) HIV have limited or no 
treatment options. Department of Health and Human Services ( HHS ) HIV treatment guidelines 
encourage these patien ts to seek clinical trials and expanded access programs.3   
 
TaiMed Biologics is currently developing i balizumab for treatment of HIV. Ibalizumab is a 
monoclonal antibody that binds to a conformational epitope on domain 2 of the extracellular 
portion of t he CD4 receptor . Ibalizumab binding reduces HIV replication by inhibiting viral entry 
into CD4+ T-cells. With this novel mechanism of action, ibalizumab has no known cross -resistance 
with oth er antiretroviral medications. Ibalizumab in combination with other antiretroviral 
medications has demonstrated safety and durable antiviral activity in clinical trials in HIV-1-infected, 
treatment -experienced patients with MDR HIV. Ibalizumab has been awarded Orphan Drug and 
Breakthrough Drug designations by the US Food and Drug Administration  (FDA) . Still, the clinical 
trial and regulatory approval process can take seve ral years to complete ; some patients who are in 
urgent need of treatment cannot wait for ibalizumab to secure approval. An expanded access to 
clinical trial is needed to provide potentially life -saving access for patients with MDR HIV and 
limited or no available treatment options.  
 
 
1.2 Clinical Studies  
Prior studies have been conducted in HIV -positive individuals using the IV formulation of 
ibalizumab , and  are summari zed here. In addition, a study of ibalizumab  administered 
subcutaneously (TMB -108) to HIV -negative at -risk volunteers has been completed.  Another study 
(TMB -121) exploring both subcutaneous and intramuscular administration routes in both HIV -
negative and HIV-positive  participants  is ongoing.  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  10    Results from the Phase 1a clinical trial (Hu5A8.01)  demonstrated that IV administration of a single 
dose of ibalizumab  to HIV -infected patients was associated with dose -dependent mean viral load 
reductions of approximately 1 log 10 in those receiving doses of 10 mg/kg or greater. Mean viral load 
reductions persisted for 2 -3 weeks. In a subsequent Phase 1b study (TNX -355.02 ), ibalizumab  was 
given to HIV -infected patients as a single agent (monotherapy) or added to failing highly active 
antiretroviral therapy ( HAART ). Multiple doses of ibalizumab  again demonstrated clinically 
significant viral load reductions (median reductio ns approximately 1 log 10) with viral load nadirs at 1 -
2 weeks. A 24 -week, double -blind, placebo -controlled, randomized, three -arm Phase 2a study 
(TNX -355.03) evaluated the safety, efficacy, and pharmacokinetics ( PK) activity of two ibalizumab  
dose regimens  (10 mg/kg and 15 mg/kg) in combination with an optimized background regimen 
(OBR ) versus placebo with an OBR in treatment -experienced patients. As in the Phase 1 program, 
the Phase 2a study clearly demonstrated the antiviral activity of ibalizumab . Viral load reductions in 
the treatment arms were statistically significantly different from placebo, with approximately 1 log 10 
reductions seen in the ibalizumab -containing arms at 24 weeks (primary endpoint) and 48 weeks. 
Also at 48 weeks, increases in CD4+ T-cell counts of approximately +50 cells/µL were observed for 
both of the active treatment arms versus virtually no change from baseline for the placebo arm (+1 
cell/µL).  
 
All single -dose and multiple -dose administrations of ibalizumab  were generally well tol erated with 
no serious adverse events (SAEs) related to study drug, no dose -limiting toxicities related to study 
drug, and no evidence of adverse effects on the CD4+ T-cells of treated patients. When compared to 
placebo (Phase 2a) the incidences, spectrum,  and intensity of AEs were similar between the active 
treatment arms and the placebo arm. While a statistically significant differen ce in incidence was not 
observed between either of the active treatment arms and the placebo arm, rash (mostly mild to 
moder ate severity) did occur more often in active treatment arms than in the placebo arm. This 
observation appears to be consistent with the known association of rash with administration of 
humanized monoclonal antibody (MAb) medications.4 The administration o f ibalizumab  was not 
associated with immunosuppression, as evidenced by the lack of any increase in infections or 
malignancies in the study population treated with ibalizumab . Intradermal skin tests performed on a 
subset of patients were also similar betwe en active treatment arms and placebo. Anti -ibalizumab  
antibodies have been detected transiently and at low titers in a small number of patients (2.4%). The 
observation of anti -ibalizumab  antibody activity was not associated with any AEs and appeared to 
have no impact on antiviral efficacy. The significance of anti -ibalizumab  antibodies is not known.  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  11    A Phase 2b clinical trial in 113 HIV -infected patients was also completed. Heavily treatment -
experienced patients enrolled in this study receive d IV doses of 800 mg of ibalizumab  every 2 weeks 
(q2wk) or 2,000  mg every 4 weeks  (q4wk) in combination with an OBR. The key primary efficacy 
endpoint was the proportion of patients with HIV -1 ribonucleic acid ( RNA ) levels below the assay 
limit (<50 copies/mL)  at Week 24. The percentages of patients with <50 copies/mL at Week 24 
were 44% and 28% for the 800 mg q2wk arm and the 2,000  mg q4wk arm respectively , in the most 
stringent intention -to-treat ( ITT) missing equals failure  (MEF ) analysis. Other noteworthy e fficacy 
endpoints included mean change from Baseline in HIV -1 RNA at Week 24 and mean change in 
CD4+ T-cell counts . The mean change from Baseline at Week 24 was -1.6 log 10 for the 800 mg q2wk 
arm and -1.5 log 10 for the 2,000  mg q4wk arm. The mean change fr om Baseline in CD4+ T-cells at 
Week 24 was +37 cells/μL for the 800 mg q2wk group and +40 cells/μL for the 2,000  mg q4wk 
group . These results are consistent with quantitative measures of immune system recovery in a 
treatment -experienced population over 24 weeks in studies of other drugs.  There was no statistically 
significant difference between the 800 mg q2wk  and 2,000  mg q4wk arms in viral load outcomes at 
24 weeks.  
 
Similar to previous studies, ibalizumab  in combination with the OBR was well tolerated in the Phase 
2b investigation. The incidences, spectrum , and intensity of AEs were similar across the two 
treatment arms. A total of 15 SAEs were reported in 14 randomized patients, and all SAEs were 
assessed as not related to study drug. The mos t frequent non -laboratory AEs were rash (13%), 
diarrhea (12%) , and headache (9%); most did not result in discontinuation. Other clinical treatment -
emergent adverse events ( TEAE s) that were reported in ≥ 5% of patients were nausea, 
nasopharyngitis, upper re spiratory tract infection, cough, oral candidiasis, vomiting, and fatigue. 
Only rash and headache were considered treatment -related TEAEs in ≥ 5% of patients on study. 
One treatment -related TEAE (moderate rash) resulted in study discontinuation.  Based on t he overall 
study results, the 800 mg q2wk dose and the 2,000  mg q4wk dose demonstrated safety and efficacy 
in this treatment -experienced HIV -positive patient population.  
 
A subcutaneous formulation of ibalizumab  has been developed and an initial Phase 1 cl inical trial 
(TMB -108) conducted . TMB -108 was a randomized, placebo -controlled, double -blind , multi -dose 
sequential escalating dose study. The dosing cohorts were 120 mg, 240 mg, and 480 mg each given 
weekly. Each subject received weekly doses of ibalizuma b subcutaneously for 4 weeks.  Subjects who 
withdrew prior to completion of dosing for non -safety -related reasons were replaced.  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  12    No SAEs  and no discontinuations due to AEs were reported on the protocol. No Grade 4 AEs 
were reported. One Grade 3 AE, “headache ,” was reported. This AE was treated with over -the-
counter medications and resolved within one day of onset. Headache was also the most frequently 
reported AE, with all other reports of headache being mild to moderate in intensity. In addition to 
headache, AEs reported in more than one patient were cough, sinus/nasal congestion, and pruritis. 
No injection site reactions were reported. Taken together, the reported results of completed clinical 
studies suggest that ibalizumab  is safe and has potent activity against HIV in humans.  
 
The phase 3 registrational study (TMB -301) was a single arm, multicenter study, conducted in 40 
treatment -experienced HIV -infected patients with m ulti-drug resistant HIV -1. Patients were treated 
with antiretrovirals for at least 6 months and were failing or had recently failed (i.e., in the last 8 
weeks) therapy to determine baseline viral load with documented HIV viral load of >1,000 
copies/mL.   
 
During Days 0 through 6, “the control period”, patients were monitored on current failing 
background regimen (or no therapy, if the patient had failed and discontinued treatment within the 8 
weeks preceding Screening). During Days 7 through 13, "the essent ial monotherapy period", 
patients continued on current failing therapy and received one 2000 mg dose (loading dose) of 
ibalizumab on Day 7. Day 7 was Baseline for the treatment period (Day 7 -Week 25). On Day 14, 
viral load was assessed for the primary end point, thereafter the background regimen was optimized 
to include at least one agent to which the patient’s virus was susceptible. Beginning at Day 21, 800 
mg of ibalizumab was administered every 2 weeks through Week 23, the “maintenance period”. 
Thirty -one patients completed the Week 25/ End of Study Visit. The primary effectiveness endpoint 
was the proportion of patients achieving a ≥0.5 log10 decrease in viral load from Day 0 to Day 7 
and from Day 7 to Day 14.  
 
At Baseline, median viral load and CD4+ T c ell counts were 4.55 log10 copies/mL (35,350 
copies/mL) and 73 cells/mm3, respectively. Baseline Overall Susceptibility Scores (OSS) was were 
0, 1, 2, or ≥2, for X (X13%), XX (X35%), XXX (X45%), and 3% of patients,  for 0, 1, and ≥2, 
respectively.  
 
In the  ITT population, a statistically significant difference was observed between the proportion of 
patients achieving a 
  0.5 log10 decrease in viral load from Day 0 to Day 7 (Control period; 2.5%; 
95% CI: 0.0006, 0.1316) and compared with the proportion achie ving a 
  0.5 log10 decrease from 
Day 7 to Day 14 after receiving a 2000 mg loading dose of ibalizumab (82.5%; 95% CI: 0.6722, 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  13    0.9266; p<0.0001). Sixty Fifty five percent of patients achieved ≥1.0 log10 reduction in viral load 
after receiving the 2000 mg lo ading dose, during the essential monotherapy period (Day 7 to Day 
14), and 55%after receiving the 2000 mg loading dose. maintained a ≥1.0 log10 reduction in viral 
load after receiving the and 800 mg q wk dose at once weekly through Week 25, during the 
main tenance period. during the essential monotherapy period (Day 7 to Day 14). The mean change 
in viral load from Baseline to Day 14 was  a 1.07 log 10  reduction and to Week 25 was a 1.64 log 10 
reduction at Day 14 was a 1.07 log10 reduction.  
 
An increase in the mean number of CD4+ T -cells of 63 cell/μL was observed from Baseline to 
Week 25.  This increase in CD4+ T -cells is indicative of the therapeutic effect over 24 weeks.  
At Week 25 after treatment with the 800 mg a 2wk maintenance dose, the mean change in  viral load 
from Day 7 was 1.6 log10 reduction with 55% and 48% of patients having a ≥1 log10 and ≥2 log10 
reduction, respectively. Viral load <50 and <200 HIV -1 RNA copies/mL was reached in 43% and 
50% of patients, respectively.  
 
The most common adverse reactions (all Grades) reported in at least 5% of subjects were diarrhea, 
dizziness, nausea, and rash.  Table 1 shows the frequency of adverse reactions occurring in 5% or 
more of subjects.  
 
Table 1.  Adverse Reactions (All Grades) Reported in ≥5% of Subjects 
Receiving ibalizumab and Optimized Background Regimen for 23 Weeks in Trial 
TMB -301 
                                                                      
 
 
 
 
                                                                                                             
 
 
*Includes pooled terms “rash”, “rash erythematous”, “rash generalized”, “rash macular”, “rash 
maculopapular”, and “rash papular”  
 
Most (90%) of t he adverse reactions reported were mild or moderate in severity.  Two subjects 
experienced severe adverse reactions: one subject had a severe rash and one subject developed 
immune reconstitution inflammatory syndrome manifested as an exacerbation of progre ssive 
multifocal leukoencephalopathy.  
  Percent of All TMB -301 Subjects  
(N=40 ) 
n (%)  
Diarrhea  3 (8%) 
Dizziness  3 (8%) 
Nausea  2 (5%) 
Rash*  2 (5%) 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  14     
Laboratory Abnormalities  
Table 2. Selected Laboratory Abnormalities ( ≥Grade 3) in Trial TMB -301 
Laboratory Parameter  % Subjects  
N=40  
Bilirubin (≥ 2.6 x ULN)  5% 
Direct Bilirubin (> ULN)  3% 
Creatinine (>1.8x ULN or 1.5x baseline)  10% 
Blood Glucose (> 250 mg/dL)  3%  
Lipase (>3.0 x ULN)  5% 
Uric Acid (>12 mg/dL)  
  3% 
Hemoglobin (< 8.5 g/dL)  3% 
Platelets (< 50,000/mm3) 3% 
Leukocytes (< 1.5 109 cells/L)  5% 
 
Neutrophils (<0.6 109 cells/L)  5% 
 
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody  
formation is highly dependent on the sens itivity and specificity of the assay. Additionally, the 
observed incidence of antibody  (including neutralizing antibody) positivity in an assay  may be 
influenced by several factors including assay  methodology, sample handling, timing of sample 
collection, concomitant medications, and underlying disease. For these reasons, comparison of the 
incidence of antibodies to ibalizumab in the studies described below with the incidence of antibodies 
in other studies or to other products  may be misleading.  All subjects enrolled in clinical trial TMB -
301 and trial TMB -202 (a Phase 2b clinical trial that studied ibalizumab administered intravenously 
as 2,000 mg every 4 weeks or 800 mg every 2 weeks; the safety and effectiveness of this dosing 
regimen has not been established), were tested for the presence of anti -ibalizumab I gG antibodies 
throughout their participation. One sample tested positive with low titer anti -ibalizumab antibodies. 
No adverse reaction or reduced efficacy was attributed to the positive sample reported in this 
subject.  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  15    1.3 Pharmacokinetic Profile  
IV administration of escalating single doses of ibalizumab  (Protocol Hu5A8.01) demonstrated that 
serum concentrations of ibalizumab  generally peaked at the end of the infusion period. Ibalizumab 
PKs were dose -dependent, as both systemic exposure and elimination half-life increased 
disproportionately with increasing dose. This indicated that the elimination of ibalizumab  is capacity 
limited and saturable at higher doses . A similar conclusion was reached after  a multiple -dose study 
of IV ibalizumab  (Protocol TNX -355.02) , which demonstrate d that the steady  state half -life 
following multiple doses of 10 and 25 mg/kg was 75 and 79 hours, respectively . The capacity -limited 
elimination is likely due to  CD4 receptor turnover, given the short half -life for ibalizumab  relative to 
endogenous IgG4 molecules. In the IV ibalizumab  studies conducted to date, there was a correlation 
between ibalizumab  trough serum concentrations of 0.3 µg/mL or higher and satura ted binding of 
CD4 (receptor occupancy) on  CD4+ T-cells, and between CD4 receptor occupancy and reductions 
in HIV viral load. Similar observations were made after subcutaneous administration of ibalizumab  
in HIV -negative volunteers, in which dose -dependent  systemic exposure indicated saturable 
elimination with the same correlation between serum concentrations and CD4 receptor occupancy. 
A new study (TMB -121) of parent erally administered ibalizumab  (subcutaneous and intramuscular) 
has been initiated to evalu ate viral load responses in HIV -infected patients.  
 
 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  16    2. Study Objectives  
 
2.1 Primary Objective s 
The primary objectives of this study are to:  
 
Cohort 1  
◼ Continue to provide ibalizumab to patients currently receiving ibalizumab treatment 
under Investigator -sponsored IND or TaiMed -sponsored protocols  
◼ Demonstrate the safety and tolerability of ibalizumab in HIV -positive patients with 
MDR HIV infection  
Cohort 2  
◼ Provide access to ibalizumab for qualifying MDR HIV -1-infected patients with limited 
treatment options  
◼ Demonstrate the safety and tolerability of ibalizumab in HIV -positive patients with 
MDR  HIV infection  
 
2.2 Secondary Objectives  
The secondary objectives of this study are to:  
 
◼ Demonstrate the antiviral activity of ibalizumab in HIV -positive patients with MDR 
HIV infection  
◼ Characterize HIV -1 sensitivity/susceptibility changes associated with protocol -defined 
virologic failure after ibalizumab administration in combination with the OBR  
◼ Determine the presence and significance of anti -ibalizumab antibodies associated with 
protocol -defined virologic failure after ibalizumab administration, if any 
(immunogenicity of ibalizumab)  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  17     
3. Study Plan  
 
3.1 Overall Design  
This Phase 3, multicenter , expanded access study will evaluate the safety and tolerability of 
ibalizumab in treatment -experienced patients infected with MDR HIV-1. Eligible patients will 
include (1) those currently receiving ibalizumab under a TaiMed -sponsored or Investigator -
spons ored IND protocol and (2) treatment -experienced patients with no history of ibalizumab 
treatment who are on a failing regimen, or who have failed and are off treatment.   
 
Patients will be enrolled in one of two Cohorts (Cohort 1 and Cohort 2):  
 
Cohort 1 ( continuing treatment)  
◼ Patients will continue on an ibalizumab containing regimen at their current dosage in 
combination with a current OBR.   
Cohort 2 (initiating ibalizumab ) 
◼ On Day 0 /Baseline , patients will receive one 2,000  mg dose (loading dose) of 
ibalizumab. The OBR will be initiated on Day 0 /Baseline  and must include at least one 
agent to which the patient’s virus is susceptible.  
◼ Beginning at Day 14, an 800 mg of ibalizumab will be admini stered every 2 weeks 
through the remainder of the study . 
Virologic failure is defined as two consecutive measurements at Week 24 or later if less than a 0.5 
log 10 decline from the Baseline viral load (see Section 9 .4 for the definition of Baseline) . 
 
Patients will be discontinued from the study at the patient’s request or if the patient becomes 
pregnant, at investigator request, for protocol violation, for virologic failure , for treatment -related 
serious or intolerable AE(s) ( Division of AIDS [ DAIDS ] criteria, see Appendix B) , or for toxicity 
(defined as two consecutive laboratory results, at least 14 days apart, with a CD4+ cell count below 
200 cells/mm3 that also represents a 50% reduction from the Baseline CD4+ cell count).  
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  18    3.2 Discussion of Trial Design  
This study is designed to assess the safety and tolerab ility of IV ibalizumab . In addition, all patients  
will receive a standard of care OBR consisting of antiretroviral medications selected by the Principal 
Investigator based upon the patient's treatment history and the results of viral resistance testing . The 
effectiveness of the treatment regimen will also be assessed  (Cohort 2 only) . Safety and tolerability 
will be evaluated by the occurrence of AEs and discontinuations. The primary evaluation of 
effectiveness will be at Day 7. Additional secondary evaluations will be conducted at Day 7 and 
other assessment time points . 
 
This is an open -label safety study to provide early access to IV ibalizumab for HIV -1-infected 
patients who have no or limited treatment options on commerciall y available antiretroviral therapy 
(ART) and who are ineligible for participation in any other Tai Med Biologics -sponsored trial  of 
ibalizumab . The safety and tolerability of IV ibalizumab in combination with an OBR  in MDR HIV -
1-infected patients with limit ed or no treatment options will be assessed.  Eligible patients already 
approved for Investigator -sponsored ibalizumab INDs (Cohort 1) will remain on Investigator -
sponsored INDs until they can be transitioned to this protocol. Upon enrollment, patients will  
continue to rece ive treatment with the previously assigned regimen : either ibalizumab 80 0 mg IV 
every 2 weeks with an OBR , or ibalizum ab 2,000  mg IV every 4 weeks with an OBR . Treatment will 
continue until treatment -limiting toxicity, virologic failure , loss to follow -up, withdrawal from the 
trial, pregnancy, discontinuation of ibalizumab  development , or commercial availability of 
ibalizumab . 
 
Eligible patients participating in TaiMed Protocol TMB -301 (who will enroll in Cohort 1  of this 
study ) will continue to receive treatment with  ibalizumab  800 mg IV every 2 weeks with an OBR  
while enrolled in this study . Treatment will continue until treatment -limiting toxicity, virologic 
failure , loss to follow -up, withdrawal from the trial, pregnancy, discontin uation of ibalizumab 
development , or commercial availability of ibalizumab . 
 
Eligible patients who are not participating in an Investigator -sponsored  or TaiMed -sponsored 
ibalizumab  IND  (Cohort 2  of this study ) will undergo a Screening period of , at most , 6 weeks. 
Patients will start treatment with ibalizumab 2,000  mg IV (loading) on Day 0 and then 800 mg IV 
(maintenance) on Day 14 and every 2 weeks thereafter. All patients will also receive an OBR  
beginning at Day 0 . Treatment will continue until treatment -limiting toxicity, virologic failure , loss to 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMB ER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  19    follow -up, withdrawal from the trial, pregnancy, discontinuation of ibalizumab development , or 
commercial availability of ibalizumab . 
 
 
3.3 Dose Selection  
Both dosages of IV ibalizumab  (2,000  mg every 4 weeks and 800 mg every 2 weeks ) were evaluated 
in the TMB -202 Phase 2b study. The results of that study indicated that higher serum concentrations 
and maximum receptor occupancy were achieved more rapidly with the 2,000  mg dose. Conversely , 
a highe r percentage of patients  on the 800 mg dose administered every 2 weeks achieved and 
maintained HIV  RNA levels below 50 copies at Week 24  compared to  patients on the 2,000  mg 
dose administered every 4 weeks. This observation may have been associated with th e trend toward 
higher trough concentrations observed with the 800 mg dose. As the AE profile of both dosages 
was similar, the d osage regimen selected  for Cohort 2 (patients initiating ibalizumab) in  this study 
reflects the optimal PK features of each dose studied in TMB -202: A single 2,000  mg loading dose 
will be followed by 800 mg maintenance doses administered every 2 weeks. This dose regimen is  
designed to combine the maximal initial drug exposure of a 2,000  mg dos age with the more durable 
exposure of the 800 mg q2week dosage . Cohort 1 patients (continuing  treatment ) will continue on 
their current successful dosing regimen s. 
 
 
3.4 Schedule of Events  
The Schedule of Events is presented in Table s 3-1 and 3-2 for Cohort 1  patients receiving 
ibalizumab 800 mg every 2 weeks , in Tables 3 -3 and 3 -4 for Cohort 1 patients receiving ibalizumab 
2,000  mg every 4 weeks , and in  Tables 3 -5 and 3-6 for patients in Cohort 2.  Throughout the study, 
patients are not required to fast before  collect ion of blood samples for safety or  effectiveness. 
However, patients should adhere to dietary recommendations as suggested for the components of 
their OBR or other concomitant medications . 
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  20    Table 3-1. Schedule of Events : Cohor t 1 – 800 mg every 2 weeks , Screening t hrough  Week 4  
 Study Visit  
Screening/ 
Day 0  Day 14  Week 4  
Visit window (days)  N/A  ±1 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG ADMINISTRATION     
Discuss the inclusion/ exclusion criteria  X   
Obtain a signed informed consent form  X   
Record demographics, medical history (general and HIV) , height  X   
Record all prior ART exposure; record all other medications within the last 30 days X   
Assess adherence to the OBR    X 
Record results of a complete physical examination X   
Record vital sign measurements  X X X 
Record the patient’s weight  X   
Record AEs  X4 X X 
Record concomitant medications   X X 
BLOOD 1 AND/OR URINE SAMPLES TO BE COLLECTED BEFORE STUDY DRUG ADMINISTRATION     
Hepatitis serology, C -reactive protein X   
Hematology, serum chemistry , urinalysis  (see Section 7.2.2 ) X   
Archive sample  X   
Serum for pregnancy test for females of childbearing potential 2  X   
Urine for pregnancy test for females of childbearing potential    X 
HIV-1 RNA (viral load)  X   
HIV-1 viral resistance sample 3  X   
CD4+ T-cell count  5 X   
Immunogenicity of ibalizumab (2 tubes x 3 mL each)  5 X   
STUDY DRUG ADMINISTRATION AND AFTER     
Administer study medication  X X X 
Record vital sign measurements  and observe (15 min.)  after infusion  X X X 
Record AEs  X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  21    1 Patients need not fast before blood sampling . 
2 Serum FSH test to be conducted on postmenopausal females at Screening only . 
3 Viral resistance testing will include assessments of reverse transcriptase, protease, integrase , and envelope (entry) genes and chemokine coreceptor util ization; the samples will be 
collected and stored, and testing will only be performed for patients who experience virologic failure while on the study.  
4 Only record AEs that are related to study procedures before administration of the first dose . 
5 Samples to be drawn within 1 hour before the start of the infusion (if infusion is scheduled for that visit).  
 
Abbreviations: AE = adverse event; ART = antiretroviral therapy; CD4+ = helper T -cell; FSH = follicle -stimulating hormone; HIV = human immunodefi ciency virus; OBR = optimized background 
regimen  
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  22    Table 3 -2. Schedule of Events: Cohort 1 – 800 mg every 2 weeks , Week 6 through end of study  
Week  Study Visit  
6 8 10 12 14 16 18 20 22 24 26 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION             
Record results of a complete physical examination          X  
Record results of an abbreviated physical examination 1    X        
Record the patient’s weight     X      X  
Record vital sign measurements  X X X X X X X X X X X 
Record AEs and concomitant medications  X X X X X X X X X X X 
Assess adherence to the OBR   X  X      X  
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED BEFORE 
STUDY DRUG ADMINISTRATION             
Hepatitis serology, C -reactive protein           X  
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )    X      X  
Archive sample     X      X  
Serum for pregnancy test for females of childbearing potential            X  
Urine for pregnancy test for females of childbearing potential   X  X  X  X    
HIV-1 RNA (viral load)     X      X  
HIV-1 viral resistance sample  3    X      X  
CD4+ T-cell count 4    X      X  
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4          X  
STUDY DRUG ADMINISTRATION AND AFTER             
Administer study medication  X X X X X X X X X X X 
Record vital sign measurements and AEs  and observe (15 min.)  after infusion  X X X X X X X X X X X 
 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  23    Table 3 -2. Schedule of Events: Cohort 1 – 800 mg every 2 weeks, Week 6 through end of study (Continued)  
Week  Study Visit  
28 30 32 34 36 38 40 42 44 46 48 50 52 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION               
Record results of a complete physical examination           X   
Record results of an abbreviated physical examination 1     X         
Record the patient’s weight      X      X   
Record vital sign measurements  X X X X X X X X X X X X X 
Records AEs and concomitant medications  X X X X X X X X X X X X X 
Assess adherence to the OBR      X      X   
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED 
BEFORE STUDY DRUG ADMINISTRATION               
Hepatitis serology, C -reactive protein            X   
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )     X      X   
Archive sample      X      X   
Serum for pregnancy test for females of childbearing potential            X   
Urine for pregnancy test for females of childbearing potential  X  X  X  X  X    X 
HIV-1 RNA (viral load)      X      X   
HIV-1 viral resistance sample 3     X      X   
CD4+ T-cell count 4     X      X   
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4           X   
STUDY DRUG ADMINISTRATION AND AFTER               
Administer study medication  X X X X X X X X X X X X X 
Record vital sign measurements and AEs and observe (15 min.) 
after infusion  X X X X X X X X X X X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  24    Table 3 -2. Schedule of Events: Cohort 1 – 800 mg every 2 weeks, Week 6 through end of study (Continued)  
Week  Study Visit  
54 56 58 60 62 64 66 68 70 72 74 76 78 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION               
Record results of a complete physical examination          X    
Record results of an abbreviated physical examination 1    X          
Record the patient’s weight     X      X    
Record vital sign measurements  X X X X X X X X X X X X X 
Records AEs and concomitant medications  X X X X X X X X X X X X X 
Assess adherence to the OBR     X      X    
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED 
BEFORE STUDY DRUG ADMINISTRATION               
Hepatitis serology, C -reactive protein               
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )    X      X    
Archive sample     X      X    
Serum for pregnancy test for females of childbearing potential           X    
Urine for pregnancy test for females of childbearing potential   X  X  X  X    X  
HIV-1 RNA (viral load)     X      X    
HIV-1 viral resistance sample 3    X      X    
CD4+ T-cell count 4    X      X    
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4           X    
STUDY DRUG ADMINISTRATION AND AFTER               
Administer study medication  X X X X X X X X X X X X X 
Record vital sign measurements and AEs and observe (15 min.) 
after infusion  X X X X X X X X X X X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  25    Table 3 -2. Schedule of Events: Cohort 1 – 800 mg every 2 weeks, Week 6 through end of study (Continued)  
Week  Study Visit  
80 82 84 86 88 90 92 94 96 98 100 102 104 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION               
Record results of a complete physical examination         X     
Record results of an abbreviated physical examination 1              
Record the patient’s weight          X     
Record vital sign measurements  X X X X X X X X X X X X X 
Records AEs and concomitant medications  X X X X X X X X X X X X X 
Assess adherence to the OBR    X      X     
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED 
BEFORE STUDY DRUG ADMINISTRATION               
Hepatitis serology, C -reactive protein          X     
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )         X     
Archive sample          X     
Serum for pregnancy test for females of childbearing potential          X     
Urine for pregnancy test for females of childbearing potential  X  X  X  X    X  X 
HIV-1 RNA (viral load)          X     
HIV-1 viral resistance sample 3         X     
CD4+ T-cell count 4         X     
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4         X     
STUDY DRUG ADMINISTRATION AND AFTER               
Administer study medication  X X X X X X X X X X X X X 
Record vital sign measurements and AEs and observe (15 min.) 
after infusion  X X X X X X X X X X X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  26    Table 3 -2. Schedule of Events: Cohort 1 – 800 mg every 2 weeks, Week 6 through end of study (Continued)  
Week  Study Visit  
106 108 110 112 114 116 118 120 122 124 126 128 130 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION               
Record results of a complete physical examination        X      
Record results of an abbreviated physical examination 1              
Record the patient’s weight         X      
Record vital sign measurements  X X X X X X X X X X X X X 
Records AEs and concomitant medications  X X X X X X X X X X X X X 
Assess adherence to the OBR   X      X      
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED 
BEFORE STUDY DRUG ADMINISTRATION               
Hepatitis serology, C -reactive protein               
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )        X      
Archive sample         X      
Serum for pregnancy test for females of childbearing potential               
Urine for pregnancy test for females of childbearing potential   X  X  X  X  X  X  
HIV-1 RNA (viral load)   X      X      
HIV-1 viral resistance sample 3  X      X      
CD4+ T-cell count 4  X      X      
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4        X      
STUDY DRUG ADMINISTRATION AND AFTER               
Administer study medication  X X X X X X X X X X X X X 
Record vital sign measurements and AEs and observe (15 min.) 
after infusion  X X X X X X X X X X X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  27    Table 3 -2. Schedule of Events: Cohort 1 – 800 mg every 2 weeks, Week 6 through end of study (Continued)  
Week  Study Visit  
132 134 136 138 140 142 144/ 
EOS  150/  
Follow up  Early 
Withdrawal5 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2  
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION           
Record results of a complete physical examination       X X X 
Record results of an abbreviated physical examination 1          
Record the patient’s weight        X X X 
Record vital sign measurements  X X X X X X X X X 
Records AEs and concomitant medications  X X X X X X X X X 
Assess adherence to the OBR  X      X X X 
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED 
BEFORE STUDY DRUG ADMINISTRATION           
Hepatitis serology, C -reactive protein         X X 
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )        X X 
Archive sample        X X X 
Serum for pregnancy test for females of childbearing potential          X 
Urine for pregnancy test for females of childbearing potential  X  X  X  X X  
HIV-1 RNA (viral load)  X      X X X 
HIV-1 viral resistance sample 3 X      X X X 
CD4+ T-cell count 4 X      X X X 
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4       X X X 
STUDY DRUG ADMINISTRATION AND AFTER           
Administer study medication  X X X X X X X   
Record vital sign measurements and AEs and observe (15 min.) 
after infusion  X X X X X X X   
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  28    1 Abbreviated physical examination will include an examination of lymph nodes, respiratory and cardiovascular systems, abdomen,  extremities, and nervous system.  
2 Patients need not fast before blood sampling . 
3 Viral resistance testing will include assessmen ts of reverse transcriptase, protease, integrase , and envelope (entry) genes and chemokine coreceptor utilization; the samples will be 
collected and stored, and testing will only be performed for patients who experience virologic failure while on the study . 
4 Samples to be drawn within 1 hour before the start of the infusion (if infusion is scheduled for that visit).  
5 Patients who withdraw or are withdrawn at any time prior to the Week 1 50 visit should have Early Withdrawal procedures performed.  
 
Abbreviations: AE = adverse event; ART = antiretroviral therapy; CD4+ = helper T -cell; EOS = end of study; FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; OBR = 
optimized ba ckground regimen  
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  29    Table 3 -3. Schedule of Events: Cohort 1 – 2,000  mg every 4 weeks , Screening through W eek 8 
 Study Visit  
Screening/  
Day 0  Week 4  Week 8  
Visit window (days)  N/A  ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG ADMINISTRATION     
Discuss the inclusion/ exclusion criteria  X   
Obtain a signed informed consent form  X   
Record demographics, medical history (general and HIV) , height  X   
Record all prior ART exposure; record all other medications within the last 30 days X   
Assess adherence to the OBR   X X 
Record results of a complete physical examination X   
Record vital sign measurements  X X X 
Record the patient’s weight  X   
Record AEs  X X X 
Record concomitant medications   X X 
BLOOD 1 AND/OR URINE SAMPLES TO BE COLLECTED BEFORE STUDY DRUG 
ADMINISTRATION     
Hepatitis serology, C -reactive protein X   
Hematology, serum chemistry, urinalysis (see Section 7.2.2 ) X   
Archive sample  X   
Serum for pregnancy test for females of childbearing potential 2  X   
Urine for pregnancy test for females of childbearing potential   X X 
HIV-1 RNA (viral load)  X   
HIV-1 viral resistance sample 3  X   
CD4+ T-cell count 4 X   
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4 X   
STUDY DRUG ADMINISTRATION AND AFTER     
Administer study medication  X X X 
Record vital sign measurements and observe (15 min.) after infusion  X X X 
Record AEs  X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  30    1 Patients need not fast before blood sampling . 
2 Serum FSH test to be conducted on postmenopausal females at Screening only . 
3 Viral resistance testing will include assessments of reverse transcriptase, protease, integrase , and envelope (entry) genes and chemokine coreceptor util ization; the samples will be 
collected and stored, and testing will only be performed for patients who experience virologic failure while on the study.  
4 Samples to be drawn within 1 hour before the start of the infusion (if infusion is scheduled for that visit).  
 
Abbreviations: AE = adverse event; ART = antiretroviral therapy; CD4+ = helper T -cell; FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; OBR = optimized background 
regimen  
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  31    Table 3 -4. Schedule of Events: Cohort 1 – 2,000 mg every 4 weeks, Week 12  through end of study  
Week  Study Visit  
12 16 20 24 28 32 36 40 44 48 52 56 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION              
Record results of a complete physical examination    X      X   
Record results of an abbreviated physical examination 1 X      X      
Record the patient’s weight  X   X   X   X   
Record vital sign measurements  X X X X X X X X X X X X 
Record AEs and concomitant medications  X X X X X X X X X X X X 
Assess adherence to the OBR  X   X   X   X   
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED BEFORE 
STUDY DRUG ADMINISTRATION              
Hepatitis serology, C -reactive protein     X      X   
Hematology, serum chemistry, urinalysis (see Section 7.2.2 ) X   X   X   X   
Archive sample  X   X   X   X   
Serum for pregnancy test for females of childbearing potential      X      X   
Urine for pregnancy test for females of childbearing potential  X X X  X X X X X  X X 
HIV-1 RNA (viral load)  X   X   X   X   
HIV-1 viral resistance sample 3 X   X   X   X   
CD4+ T-cell count 4 X   X   X   X   
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4    X      X   
STUDY DRUG ADMINISTRATION AND AFTER              
Administer study medication  X X X X X X X X X X X X 
Record vital sign measurements and AEs and observe (15 min.) after infusion  X X X X X X X X X X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  32    Table 3 -4. Schedule of Events: Cohort 1 – 2,000  mg every 4 weeks, Week 12 through end of study  (Continued)  
Week  Study Visit  
60 64 68 72 76 80 84 88 92 96 100 104 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION              
Record results of a complete physical examination    X      X   
Record results of an abbreviated physical examination 1 X            
Record the patient’s weight  X   X      X   
Record vital sign measurements  X X X X X X X X X X X X 
Record AEs and concomitant medications  X X X X X X X X X X X X 
Assess adherence to the OBR  X   X   X   X   
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED BEFORE 
STUDY DRUG ADMINISTRATION              
Hepatitis serology, C -reactive protein     X      X   
Hematology, serum chemistry, urinalysis (see Section 7.2.2 ) X   X      X   
Archive sample  X   X      X   
Serum for pregnancy test for females of childbearing potential     X      X   
Urine for pregnancy test for females of childbearing potential  X X X  X X X X X  X X 
HIV-1 RNA (viral load)  X   X      X   
HIV-1 viral resistance sample 3 X   X      X   
CD4+ T-cell count 4 X   X      X   
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4    X      X   
STUDY DRUG ADMINISTRATION AND AFTER              
Administer study medication  X X X X X X X X X X X X 
Record vital sign measurements and AEs and observe (15 min.) after infusion  X X X X X X X X X X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  33    Table 3 -4. Schedule of Events: Cohort 1 – 2,000  mg every 4 weeks, Week 12 through end of study  (Continued)  
Week  Study Visit  
108 112 116 120 124 128 132 136 140 144 
EOS  150 
Follow  up Early 
Withdrawal5 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2  
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION              
Record results of a complete physical examination    X      X X X 
Record results of an abbreviated physical examination 1             
Record the patient’s weight     X      X X X 
Record vital sign measurements  X X X X X X X X X X X X 
Record AEs and concomitant medications  X X X X X X X X X X X X 
Assess adherence to the OBR  X   X   X   X X X 
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED BEFORE 
STUDY DRUG ADMINISTRATION              
Hepatitis serology, C -reactive protein            X X 
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )    X       X X 
Archive sample     X      X X X 
Serum for pregnancy test for females of childbearing potential             X 
Urine for pregnancy test for females of childbearing potential  X X X X X X X X X X X  
HIV-1 RNA (viral load)  X   X   X   X X X 
HIV-1 viral resistance sample 3 X   X   X   X X X 
CD4+ T-cell count 4 X   X   X   X X X 
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4    X      X X X 
STUDY DRUG ADMINISTRATION AND AFTER              
Administer study medication  X X X X X X X X X X   
Record vital sign measurements and AEs and observe (15 min.) after infusion  X X X X X X X X X X   
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  34    1 Abbreviated physical examination will include an examination of lymph nodes, respiratory and cardiovascular systems, abdomen,  extremities, and nervous system.  
2 Patients need not fast before blood sampling . 
3 Viral resistance testing will include assessments of reverse transcriptase, protease, integrase , and envelope (entry) genes and chemokine coreceptor utilization; the samples will be 
collected and stored, and testing will only be performed for patients who experience virolo gic failure while on the study.  
4  Samples to be drawn within 1 hour before the start of the infusion (if infusion is scheduled for that visit) . 
5 Patients who withdraw or are withdrawn at any time prior to the Week 1 50 visit should have Early Withdrawal procedures performed.  
 
Abbreviations: AE = adverse event; ART = antiretroviral therapy; CD4+ = helper T -cell; EOS = end of study; FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; OBR = 
optimized background regimen  
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  35    Table 3 -5. Schedule of Events: Cohort 2 , Screening through Day 14  
 Screening  Study Visit  
Weeks -6 to -1 Day 0  
Baseline  Day 7  Day 14  
Visit window (days)  N/A  N/A  ±1 ±1 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG ADMINISTRATION      
Discuss the inclusion/ exclusion criteria  X    
Obtain a signed informed consent form  X    
Record demographics, medical history (general and HIV) , height  X    
Record all prior ART exposure or changes to ART; record all other medications within the last 30 
days1 X X   
Obtain documentation of HIV -1 infection 2 X    
Obtain documentation of viral resistance, if available (within 6 months of Screening) ; select OBR  X    
Initiate the selected OBR   X   
Assess adherence to the OBR    X  
Record results of a complete physical examination X X   
Record results of an abbreviated physical examination  3   X  
Record vital sign measurements  X X X X 
Record the patient’s weight  X X   
Record AEs  X4 X 4  X X 
Record concomitant medications    X X 
BLOOD 5 AND/OR URINE SAMPLES TO BE COLLECTED BEFORE STUDY DRUG 
ADMINISTRATION      
Hepatitis serology, C -reactive protein X    
Hematology, serum chemistry , urinalysis  (see Section 7.2.2 ) X X X  
Archive sample   X X  
Serum for pregnancy test for females of childbearing potential 6  X    
Urine for pregnancy test for females of childbearing potential   X   
HIV-1 RNA (viral load)  X X X X 
HIV-1 antibody level, if written documentation not provided  X    
HIV-1 viral resistance sample 7  X X X X 
CD4+ T-cell count  8 X X X X 
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 8  X   
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  36    Table 3 -5. Schedule of Events: Cohort 2, Screening through Day 14 (Continued)  
 Screening  Study Visit  
Weeks -6 to -1 Day 0  
Baseline  Day 7  Day 14  
STUDY DRUG ADMINISTRATION AND AFTER      
Administer study medication 9  X  X 
Record vital sign measurements after infusion10  X  X 
Record AEs   X  X 
 
1 All prior ART will be recorded at Screening; Day 0 visit will only record changes to ART . 
2 An HIV  antibody test will be completed at Screening if official, signed, written documentation is unavailable . 
3 Abbreviated physical examination includes examination of lymph nodes, respiratory and cardiovascular systems, abdomen, extrem ities, and nervous system . 
4 Only record AE s that are related to study procedures before administration of the first dose . 
5 Patients need not fast before blood sampling . 
6 Serum FSH test to be conducted on postmenopausal females at Screening only . 
7 Viral resistance testing will include assessment s of reverse transcriptase, protease, integrase , and envelope (entry) genes and chemokine coreceptor utilization ; the samples will be 
collected and stored, and testing will only be performed for patients who experience virologic failure while on the study.  
8 Samples to be drawn within 1 hour before the start of the infusion (if infusion is scheduled for that visit).  
9  All patients in Cohort 2 must be observed for 1 hour after the completion of study drug administration. If the patient does not experi ence an AE(s) related to the infusion (local or systemic) 
through and including the second infusion on Day 14, then the observation time can be reduced to 15 minutes thereafter.  
10 Record vital signs after infusion (if infusion is completed at that visit).  
Abbreviations: AE = adverse event; ART = antiretroviral therapy; CD4+ = helper T -cell; FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; OBR = optimized background 
regimen  
 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  37    Table 3 -6. Schedule of Events: Cohort 2 , Week 4 through en d of study  
Week  Study Visit  
4 6 8 10 12 14 16 18 20 22 24 26 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION              
Record results of a complete physical examination X          X  
Record results of an abbreviated physical examination 1     X    X    
Record the patient’s weight  X    X    X  X  
Record vital sign measurements  X X X X X X X X X X X X 
Record AEs and concomitant medications  X X X X X X X X X X X X 
Assess adherence to the OBR  X  X   X    X  X  
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED BEFORE 
STUDY DRUG ADMINISTRATION              
Hepatitis serology, C -reactive protein            X  
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )     X      X  
Archive sample      X      X  
Serum for pregnancy test for females of childbearing potential             X  
Urine for pregnancy test for females of childbearing potential  X  X  X  X  X    
HIV-1 RNA (viral load)  X X X  X  X  X  X  
HIV-1 viral resistance sample 3 X X X  X  X  X  X  
CD4+ T-cell count 4 X X   s X  X  X  X  X  
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4           X  
STUDY DRUG ADMINISTRATION AND AFTER              
Administer study medication  5 X X X X X X X X X X X X 
Record vital sign measurements and AEs after infusion  X X X X X X X X X X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  38    Table 3 -6. Schedule of Events: Cohort 2, Week 4 through end of study  (Continued)  
Week  Study Visit  
28 30 32 34 36 38 40 42 44 46 48 50 52 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION               
Record results of a complete physical examination           X   
Record results of an abbreviated physical examination 1   X    X       
Record the patient’s weight    X  X  X    X   
Record vital sign measurements  X X X X X X X X X X X X X 
Records AEs and concomitant medications  X X X X X X X X X X X X X 
Assess adherence to the OBR    X    X    X   
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED 
BEFORE STUDY DRUG ADMINISTRATION               
Hepatitis serology, C-reactive protein            X   
Hematology, serum chemistry, urinalysis (see Section 7.2.2 ) X    X      X   
Archive sample  X    X      X   
Serum for pregnancy test for females of childbearing potential            X   
Urine for pregnancy test for females of childbearing potential  X  X  X  X  X    X 
HIV-1 RNA (viral load)  X    X      X   
HIV-1 viral resistance sample 3 X    X      X   
CD4+ T-cell count 4 X    X      X   
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4            X   
STUDY DRUG ADMINISTRATION AND AFTER               
Administer study medication  5 X X X X X X X X X X X X X 
Record vital sign measurements and AEs after infusion  X X X X X X X X X X X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  39    Table 3 -6. Schedule of Events: Cohort 2, Week 4 through end of study (Continued)  
Week  Study Visit  
54 56 58 60 62 64 66 68 70 72 74 76 78 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION               
Record results of a complete physical examination          X    
Record results of an abbreviated physical examination 1    X          
Record the patient’s weight     X      X    
Record vital sign measurements  X X X X X X X X X X X X X 
Records AEs and concomitant medications  X X X X X X X X X X X X X 
Assess adherence to the OBR     X      X    
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED 
BEFORE STUDY DRUG ADMINISTRATION               
Hepatitis serology, C -reactive protein               
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )    X      X    
Archive sample     X      X    
Serum for pregnancy test for females of childbearing potential           X    
Urine for pregnancy test for females of childbearing potential   X  X  X  X    X  
HIV-1 RNA (viral load)     X      X    
HIV-1 viral resistance sample 3    X      X    
CD4+ T-cell count 4    X      X    
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4           X    
STUDY DRUG ADMINISTRATION AND AFTER               
Administer study medication 5 X X X X X X X X X X X X X 
Record vital sign measurements and AEs after infusion  X X X X X X X X X X X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  40    Table 3 -6. Schedule of Events: Cohort 2, Week 4 through end of study (Continued)  
Week  Study Visit  
80 82 84 86 88 90 92 94 96 98 100 102 104 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION               
Record results of a complete physical examination         X     
Record results of an abbreviated physical examination 1   X           
Record the patient’s weight    X      X     
Record vital sign measurements  X X X X X X X X X X X X X 
Records AEs and concomitant medications  X X X X X X X X X X X X X 
Assess adherence to the OBR    X      X     
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED 
BEFORE STUDY DRUG ADMINISTRATION               
Hepatitis serology, C -reactive protein          X     
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )   X      X     
Archive sample    X      X     
Serum for pregnancy test for females of childbearing potential          X     
Urine for pregnancy test for females of childbearing potential  X  X  X  X    X  X 
HIV-1 RNA (viral load)    X      X     
HIV-1 viral resistance sample 3   X      X     
CD4+ T-cell count 4   X      X     
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4          X     
STUDY DRUG ADMINISTRATION AND AFTER               
Administer study medication 5 X X X X X X X X X X X X X 
Record vital sign measurements and AEs after infusion  X X X X X X X X X X X X X   
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  41    Table 3 -6. Schedule of Events: Cohort 2, Week 4 through end of study (Continued)  
Week  Study Visit  
106 108 110 112 114 116 118 120 122 124 126 128 130 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2 
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION               
Record results of a complete physical examination        X      
Record results of an abbreviated physical examination 1              
Record the patient’s weight         X      
Record vital sign measurements  X X X X X X X X X X X X X 
Records AEs and concomitant medications  X X X X X X X X X X X X X 
Assess adherence to the OBR   X      X      
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED 
BEFORE STUDY DRUG ADMINISTRATION               
Hepatitis serology, C -reactive protein               
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )        X      
Archive sample         X      
Serum for pregnancy test for females of childbearing potential               
Urine for pregnancy test for females of childbearing potential   X  X  X  X  X  X  
HIV-1 RNA (viral load)   X      X      
HIV-1 viral resistance sample 3  X      X      
CD4+ T-cell count 4  X      X      
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4         X      
STUDY DRUG ADMINISTRATION AND AFTER               
Administer study medication 5 X X X X X X X X X X X X X 
Record vital sign measurements and AEs after infusion  X X X X X X X X X X X X X 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  42    Table 3 -6. Schedule of Events: Cohort 2, Week 4 through end of study (Continued)  
Week  Study Visit  
132 134 136 138 140 142 144/  
EOS  150/  
Follow up  Early 
Withdrawal6 
Visit window (days)  ±2 ±2 ±2 ±2 ±2 ±2 ±2 ±2  
ACTIVITIES TO BE COMPLETED BEFORE STUDY DRUG 
ADMINISTRATION           
Record results of a complete physical examination       X X X 
Record results of an abbreviated physical examination 1          
Record the patient’s weight        X X X 
Record vital sign measurements  X X X X X X X X X 
Records AEs and concomitant medications  X X X X X X X X X 
Assess adherence to the OBR  X      X X X 
BLOOD 2 AND/OR URINE SAMPLES TO BE COLLECTED 
BEFORE STUDY DRUG ADMINISTRATION           
Hepatitis serology, C -reactive protein         X X 
Hematology, serum chemistry, urinalysis (see Section 7.2.2 )        X X 
Archive sample        X X X 
Serum for pregnancy test for females of childbearing potential          X 
Urine for pregnancy test for females of childbearing potential  X  X  X  X X  
HIV-1 RNA (viral load)  X      X X X 
HIV-1 viral resistance sample 3 X      X X X 
CD4+ T-cell count 4 X      X X X 
Immunogenicity of ibalizumab (2 tubes x 3 mL each) 4        X X X 
STUDY DRUG ADMINISTRATION AND AFTER           
Administer study medication 5 X X X X X X X   
Record vital sign measurements and AEs after infusion  X X X X X X X   
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEM BER 2017  
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  43    1 Abbreviated physical examination includes examination of lymph nodes, respiratory and cardiovascular systems, abdomen, extrem ities, and nervous system . 
2  Patients need not fast before blood sampling . 
3  Viral resistance testing will include assessments of  reverse transcriptase, protease, integrase , and envelope (entry) genes and chemokine coreceptor utilization ; the samples will be 
collected and stored, and testing will only be performed for patients who experience virologic failure while on the study.  
4 Samples are to be drawn within 1 hour before the start of the infusion (if infusion is scheduled for that visit) . 
5  All patients in Cohort 2 must be observed for 1 hour after the completion of study drug administration. If the patient does not experience a n AE(s) related to the infusion (local or systemic) 
through and including the second infusion on Day 14, then the observation time can be reduced to 15 minutes thereafter.  
6 Patients who withdraw or are withdrawn at any time prior to the Week 102 visit sho uld have Early Withdrawal procedures performed.  
Abbreviations: AE = adverse event; ART = antiretroviral therapy; CD4+ = helper T -cell; EOS = end of study; FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; OBR = 
optimized background re gimen  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  44    3.5 Effectiveness Assessments  
The primary effectiveness variable is the proportion of patients achieving a ≥0.5 log 10 decrease from 
Baseline in viral load at Day 7 (assessed for Cohort 2 only) . 
 
Secondary effectiveness variables wil l be the following:  
 
◼ Proportion of patients with HIV -1 RNA levels <50 copies/mL and <400 copies/mL at 
assessment time points  (assessed for Cohort 2 only)  
◼ Mean change from Baseline in viral load at Day 7 and all assessment time points  
(assessed for Cohort 2  only)  
◼ Proportion of patients achieving a ≥0.5 log 10 and ≥1.0 log 10 decrease from Baseline in 
viral load at all assessment time points  (assessed for Cohort 2 only)  
◼ HIV-1 sensitivity/susceptibility changes associated with virologic failure after 
administration of ibalizumab  
 
3.6 Safety Assessments  
Safety assessments will include the results of the following measurements  through out the study : 
 
◼ Physical examinations  
◼ Vital sign measurements  
◼ Clinical laboratory parameters (hematology, serum chemistry, and urinalysis)  
◼ Monitoring of AEs and concomitant medications  
◼ Incidence of Class C events as defined by the Centers for Disease Control and 
Prevention ( CDC ) Classification System for HIV Infection (Appendix A)  
◼ Anti-ibalizumab antibody levels (im munogenicity of ibalizumab)  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  45    4. Study Treatments  
 
4.1 Study Drug Dosage and Administration  
There are two different ibalizumab IV drug product vial configurations available for use in this 
study:  
 
Current Drug Lots In Use  
(1) vials with a 1.3 3 mL injection  volume and 200 mg ibalizumab per vial  (Lots 201509019 and 
201505012) .  
 
Patients receiving ibalizumab in study TMB -301, who will enroll into Cohort 1 of this study, and 
patients initiating ibalizumab in Cohort 2 will receive only vials with a 1.33 mL inje ction volume and 
200 mg ibalizumab per vial.  
 
Previous Drug Lot that is Depleted  
(2) vials with a 1.2 mL injection volume and 180 mg ibalizumab per vial (Lot 201403001.  This 
information is provided only in the event that Cohort 1 sites , with patients who  were previously 
under Investigator sponsored IND protocols, may still have this lot in their inventory).  
 
All ibalizumab drug product to be used in this study will be at a concentration of 150 mg/mL.  
 
 
 
 
4.1.1  Cohort 1  
Patient s in Cohort 1 will continue receiving ibalizumab via IV infusion  at the currently assigned 
dosage : either 800 mg q2 wk or 2,000  mg q4wk .  
 
 
(Lots 201509019 and 201505012 ) 
For patients enrolling into this study from study TMB -301, study drug will be provided in open -
labeled cartons of 10 vials at 1.33 mL/200 mg each. For the 800 mg q2wk doses, 4 vials are to be 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  46    used. Using a sterile syringe, 1.33 mL is withdrawn from each of  the vials to be used and injected 
into a 250 mL infusion bag of normal saline. Administration of the prepared infusion should begin 
no more than 6 hours after the time of preparation.  
 
(Lot 201403001 ) 
Until the supply of drug product currently allocated f or use in Cohort 1 patients enrolling from 
Investigator -sponsored INDs is exhausted, study drugs for these patients will continue to be 
provided in open -labeled cartons containing 10 vials at 1.2 mL/180 mg each.  
• For the 2,000 mg q4wk doses (adjusted to 2, 010 mg for this vial configuration), 13.4 mL 
total volume of ibalizumab drug product is required for each administration.  
• For the 800 mg q2wk doses (adjusted to 810 mg for this vial configuration), 5.4 mL total 
volume of ibalizumab drug product is require d for each administration.  
Using a sterile syringe, the required content is withdrawn from each of the vials to be used and 
injected into a 250 mL infusion bag of normal saline. Administration of the prepared infusion 
should begin no more than 6 hours aft er the time of preparation.  
 
When the 1.2 mL, 180 mg/vial drug product is exhausted, patients enrolled in Cohort 1 from 
Investigator -sponsored INDs will be switched to the 1.33 mL, 200 mg/vial drug product. Study 
drug will then be provided in open -labeled cartons of 10 vials at 1.33 mL/200 mg each.  
• For the 2,000 mg q4wk doses, all 10 vials in a carton are to be used.  
• For the 800 mg q2wk doses, 4 vials are to be used.  
Using a sterile syringe, 1.33 mL is withdrawn from each of the vials to be used and inje cted into a 
250 mL infusion bag of normal saline. Administration of the prepared infusion should begin no 
more than 6 hours after the time of preparation.  
 
4.1.2  Cohort 2  
(Lots 201509019 and 201505012 ) 
Study drug will be administered via IV infusion at a d ose of 2,000  mg on one occasion (Day 
0/Baseline ), followed 2 weeks later (Day 14) by doses of 800 mg administered once every 2 weeks 
through the remainder of the study . 
 
Study drug will be provided in  open -labeled  cartons  of 10 vials each.  
• For the 2,000  mg doses, a ll 10 vials in a carton  are to be used.  
• For the 800 mg doses, four vials are to be used.  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  47    Using a sterile syringe, 1.33 mL  is withdrawn from each of the vials to be used  and injected into a 
250 mL infusion bag of normal saline . Administration of the prepared infusion should begin no 
more than 6 hours after the time of preparation.  
 
 
4.1.3  Administration  
The infusion should be administered in the cephalic vein of the patient’s right or left arm. If this 
vein is not accessi ble, an appropriate vein located elsewhere can be used. For patients initiating 
ibalizumab in Cohort 2, t he duration of the infusion should be no less than 30 minutes during the 
first two study drug administrations. If no infusion -associated AEs have occur red after two 
administrations, the duration of the infusion can be decreased to no less than 15 minutes.  
 
The start and stop times of each infusion will be recorded in an Electronic Data Capture (EDC) 
system, along with the site of administration. The dat e of use and the patient’s study identification 
(ID) number and initials will be recorded.  
 
All Cohort 2 patients must be observed for 1 hour after completion of study drug administration for 
at least the first two administrations  (Day 0 /Baseline and Day 14). If the patient does not experience 
an AE(s) related to the infusion (local or systemic) during the first two infusions, then the post -
infusion observation time can be reduced to 15 minutes thereafter.  
 
In addition to the study drug, all patients will r eceive an OBR, which is a standard -of-care regimen 
selected by the investigator based upon treatment history and the results of re cent viral resistance 
testing. For patients enrolling into Cohort 2, previous  resistance testing done  within 6 months prior 
to Screening must demonstrate that the patient’s viral isolate is sensitive/susceptible to a minimum 
of one of the agents selected for the OBR. As part of the OBR, t he patient must be willing and able 
to take at least one of the agents to which their virus i s sensitive/susceptible.  
 
 
4.2 Prohibited Medications and Restrictions  
Use of and changes in concomitant medications will be recorded in the patient’s source documents 
and the EDC system. All prescription drugs, herbal products, vitamins, minerals, and ove r-the-
counter medications are to be recorded.  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  48     
Any concomitant medication , with the exception of those listed in Section 4.4.2  for Cohort 2 
patients , may be given at the discretion of the investigator. However, the investigator has the 
responsibility of ensuring that details regarding the concomitant medication are recorded for the 
patient in the EDC system. Complete information is expected for any medication prescribed during 
the trial.  
 
The prescribing information for all concomitant m edications should be reviewed carefully. The 
guidance provided in the respective contraindications, warning s, and precautions section for any 
medication must be followed to prevent any potentially serious or life -threatening drug interactions.  
 
For patient s enrolled into Cohort 2 only, t he following medications are not to be administered 
concomitantly:  
 
◼ Therapeutic HIV vaccines from Screening until study participation ends  
◼ Any vaccines during the 7 days before Day 0/ Baseline  through Day 14 of the study  
◼ All investigational drugs from 30 days before Day 0/ Baseline  and throughout the study 
(except investigational antiretroviral medications as a component of the OBR)  
In addition, radiation therapy is not allowed  for patients in C ohort 2  from 28 days before first 
administration of study drug to the last administration of study drug. Patients receiving radiation 
therapy are not allowed to enter Cohort 2 of the study; however, if a patient in Cohort 2 develops a 
condition that requir es radiation  but does not disqualify them from study participation for any other 
reason, then this event would need to be discussed with the medical monitor.  
 
First-dose, generalized, self -limiting skin rash has been described with therapeutic MAbs .5,6 Re-
challenge in such an event is at the discretion of the investigator. While there is no recommendation 
for premedication with diphenhydramine, acetaminophen , or corticosteroids, these medications have 
been used prior to the administration of other MAbs.7 Any patient who experiences anaphylactoid 
symptoms that are considered to be related to the study drug (possibly, probably, definitely) must 
have study drug discontinued and be withdrawn from the study immediately. Severe post -infusion 
reaction management typically includes corticosteroids, oxygen , and IV fluids, based on the severity 
and symptoms.7 Refer to Appendix C  for further information on the management of suspected 
anaphylactoid reactions.  Study drug should only be administered in a setti ng that allows for rapid 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  49    access to emergency cardiopulmonary support services in the event of a life -threatening infusion - 
related AE (e.g., anaphylaxis).  
 
 
4.3 Measurement of Patient Adherence  
Patient adherence will require the availability of the patient  at the study site to receive the dose and 
the patient’s willingness/ability to receive the entire dose. The receipt of the entire dose is assured, 
as each dose is given as an IV infusion by a trained professional from the clinical site and the event 
is recorded.  Adherence to the OBR will also be recorded.  
 
 
4.4 Missed Doses of Study Drug  
4.4.1  Cohort 1  
Patients should receive study drug per the Schedule of Events (Section 3.4). A missed dose is 
defined as any dose of study drug that is not administered wit hin the study visit window. Patients 
who miss doses of study medication  for two consecutive dosing intervals (i.e. , >28 days without a 
study drug infusion) of 800 mg dosage or one and one -half dosing intervals (i.e. , >42 days without a 
study drug infusion) of the 2,000  mg dose may be withdrawn from the study.  
 
Missed Dose s. If a dose is missed, the missed dose should be administered at the first opportunity. 
If an 800 mg dose is  missed and cannot be administered at least 3 days before the next scheduled 
dose, it should be skipped . If a 2,000  mg dose is missed and cannot be administered at least 5 days 
before the next scheduled dose, it should be skipped .  
 
End of study ( EOS ) procedures should be performed as soon as possi ble after the patient qualifies 
for withdrawal due to missed doses. Patients who are withdrawn from the study for missed doses 
may not be permitted to participate in other ibalizumab protocols.  
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  50    4.4.2  Cohort 2  
Patients should receive study drug per the Schedule of Events (Section 3.4 ). A missed dose is 
defined as any dose of study drug that is not administered within the study visit window. P atients 
who miss doses of study medication  for two consecutive dosing intervals (i.e., >28 days without a 
study drug infusion) or miss greater than two doses cumulative ly will be withdrawn from the study. 
EOS procedures should be performed as soon as possible  after the patient qualifies for withdrawal 
due to missed doses.  Patients who are withdrawn from the study for missed doses may not be 
permitted to participate in other ibalizumab  protocols.  
 
Missed Initial ( Loading ) Dose . If the initial 2,000  mg dose (loading dose) of study drug is 
administered outside the treatment window, the  dose should be administered at the first available 
opportunity and the timing of subsequent doses should be adjusted to coincide with the actual 
administ ration time of the first dose.  
 
Missed Maintenance Dose (3-7 days) . If a dose of 800 mg (maintenance dose) of study drug  is 
missed by going beyond the scheduled dosing day  by 3-7 days , a loading dose of 2,000  mg (reload) 
should be administered at the next available opportunity. The reload dose would substitute for the 
maintenance dose that was missed. All other visit procedures would not change other than the dose 
amount administered  (i.e., 2,000  mg reload dose substituted  for 800 mg maintenance dose) . The 
scheduling of subsequent visits will not be adjusted . 
 
Example:  If a patient is scheduled to receive study drug on D ay 49 (Week 7) but cannot come in 
until D ay 55, the patient should receive  a 2,000  mg loading dose (reloa d) on D ay 55. The subsequent 
dose should be 800 mg and scheduled for D ay 63 (Week 9)  (±2 day window).  The patient should 
continue on the original visit schedule . 
 
Missed Maintenance Dose (>7 days and < 14 days) . If a dose of 800 mg (maintenance dose) of 
study drug is missed by going beyond the scheduled dosing day by more than 7 days but less than 14 
days, the patient should receive a 2,000  mg dose (reload) at the next available opportunity. The 
missed dose should be recorded as a missed dose/missed visit.  A 2,000  mg reload dose administered 
between >7 days and < 14 days beyond the scheduled dosing date will not substitute for the missed 
dose. The 2,000  mg reload dose will substitute for the next scheduled 800 mg maintenance dose. 
Study procedures for the visit subsequent to the missed dose/missed visit should be performed 
along with the administration of the 2,000  mg reload dose. The dosing schedule should be adjusted 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  51    such that the following  800 mg maintenance dose  should be scheduled 2 week s after the reload dose 
was administered.  NOTE: Week 102/EOS  procedures should be performed without regard to dose 
window whenever the visit occurs . 
 
Example:  If a patient is scheduled to receive study drug on Day 49 (Week 7) but cannot come in 
until D ay 58, the patient should receive a 2,000  mg loading dose (reload) on D ay 58. Study 
procedures for D ay 49 (Week 7)  are recorded as missed.  Study procedures for D ay 63 (Week 9)  are 
performed along with the administration of the 2,000  mg reload dose. The dose following the reload  
dose should be 800mg and scheduled for D ay 72 (±2 day window) . The visit schedule would be 
adjusted to 800  mg every 2 weeks from the day the drug was ac tually administered . 
 
No adjustments to dosage or dosing schedules are required for a missed dose that occurs before the 
dosing window.  However, any dose administered  before the dosing window is also considered a 
missed dose.  
 
 
4.5 Study Drug Description  
The Sponsor or designee will provide the Research Pharmacists at the sites with vials containing 
study drug (active ibalizumab ) manufactured under current Good Manufacturing Practices ( cGMP ). 
Ibalizumab is provided as a parenteral formulation in a 2 mL, cle ar-glass vial. The drug product 
contains ibalizumab  at a concentration of 150 mg/mL, histidine United States Pharmacopoeia 
(USP), sucrose, sodium chloride, polysorbate 80, and water for injection USP at pH 6.0. Each vial 
contains either at least 1.2 mL of fluid delivering a total of 180 mg study drug per vial (Lot 
201403001) or at least 1.33 mL of fluid  delivering  a total of 200  mg study drug  per vial  (Lots 
201509019 and 201505012) . Labeling will clearly identify the configuration of vials in each carton 
and of each individual vial . 
 
 
4.6 Study Drug Packaging, Storage , and Disposal  
Study drug is provided as a single -use parenteral f ormulation in a 2 mL, clear -glass vial containing 
either at least 1.2 mL (Lot 204103001) or at least 1.33 mL (Lots 201509019 and 201505012)  of drug  
product . The stability of the ibalizumab  drug product at 2ºC to 8ºC is evaluated in ongoing studies. 
Study d rug will be shipped under refrigerated conditions with a temperature -monitoring device. 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  52    Ibalizumab vials should be stored refrigerated at 2°C to 8°C (but NOT FROZEN) and protected 
from light. Investigator sites must store the investigational product in a s ecure location and maintain 
a temperature log of the storage conditions.  
 
The temperature must be continuously monitored with a continuous -monitoring temperature 
device. Temperature logs must be available for review at each site -monitoring visit. Temperatu re 
excursions outside the required limits should be reported promptly to the Sponsor , and the affected 
study drug should not be administered to any study patients  until further instruction. The Sponsor 
or designee will investigate temperature excursions an d adjudicate the disposition of any affected 
study drug.  
 
Any spent vials or remaining contents of used vials should be destroyed according to the site’s 
procedures for spent vial destruction and disposal , but only after complete drug accountability 
record s have been reviewed and accepted during routine monitoring and after written permission 
has been given for spent vial destruction. The destruction should be recorded.  
 
 
4.7 Study Drug Accountability  
The investigator will maintain accurate records of receipt of the entire supply of the study drug, 
including when, how much  of, and condition s under which the study drug is received, dispensed, 
and destroyed by site personnel. In addition, the administration of study drug to each patient should 
be document ed to the vial level for each infusion (i.e., lot number of every vial for that infusion, 
time of infusion bag preparation, time of administration, and documentation of full infusion 
received). Reasons for departure from the expected dispensing regimen mus t also be recorded. Drug 
accountability will be reviewed and documented at each study visit. Reconciliation and accountability 
of study drug will be done throughout the study during the monitoring visits. After the completion 
of the study, the Sponsor or d esignee may authorize the site to dispose of unused supplies of the 
investigational drug, provided this alternative disposition does not expose humans to risks from the 
drug. The Sponsor or designee shall maintain written records of all drug disposition s, which will 
include the name of the investigator ; the date, quantity, batch , or code of each such shipment ; and 
method of disposal.  
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  53    5. Patient  Enrollment  
 
It is anticipated that approximately 50 patient s will be enrolled  at approximately 50 sites in North 
America  and Taiwan ; however , the numbers of participating patients and sites will not be limited 
and may exceed 50 . Patient s will be enrolled only if they meet all of the inclusion criteria and none 
of the exclusion crit eria. 
 
 
5.1 Inclusion Criteria  
Patients may be enrolled in Cohort 1 if they meet both of the following criteria:  
1. Are currently receiving ibalizumab via other TaiMed -sponsored or Investigator -
sponsored IND protocol  
2. Are capable of understanding and have volu ntarily signed the informed consent 
document  
Patients may be enrolled in Cohort 2 if they meet all of the following criteria:  
1. Are 18 years of age or older  
2. Are capable of understanding and have voluntarily signed the informed consent 
document  
3. Have documente d HIV -1 infection by official, signed, written history (e.g., laboratory 
report) ; otherwise , an HIV -antibody test will be performed  
4. Are able and willing to comply with all protocol requirements and procedures  
5. Have a viral load >1 ,000 copies/mL and document ed resistance to at least one 
antiretroviral medication from each of three classes of antiretroviral medications as 
measured by previous resistance testing  (resistance testing is not provided by the study 
for qualification purposes)  
6. Have a history of at least 6 months on antiretroviral treatment  
7. Are receiving a failing antiretroviral regimen OR have failed and are off therapy  
8. Have viral sensitivity/suscepti bility to at least one antiretroviral agent other than 
ibalizumab, as determined by previous  resistance test  performed within 6 months prior 
to Screening  and be willing and able to be treated with at least one agent to which the 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  54    patient’s viral isolate is fully sensitive/susceptible according to the Screening resistance 
tests as a component of the OBR  
9. If sexually active, are willing to use an effective method of contraception during the 
study and for 30 days after the last administration of the study drug  
 
5.2 Exclusion Criteria  
There are no Exclusion Criteria for patients meeting the Inclusion Criteria for Cohort 1.  
 
For Cohort 2, patients having or meeting any of the following conditions or characteristics will be 
excluded from the study:  
1. Eligible for par ticipation in other TaiMed Biologics -sponsored clinical trials  of ibalizumab  
2. Any significant diseases (other than HIV -1 infection) or clinically significant findings, 
including psychiatric and behavioral problems, determined from Screening, medical history , 
and/or physical examination that, in the investigator’s opinion, would preclude the patient 
from participating in this study  
3. Any significant acute illness within 1 week before the first administration of investigational 
medication  on this study  
4. Any activ e infection secondary to HIV requiring acute therapy; however, patients who 
require maintenance therapy (i.e., secondary prophylaxis for opportunistic infections) will be 
eligible for the study  
5. Any immunomodulating therapy (including interferon), systemic steroids, or systemic 
chemotherapy within 4 weeks before Day 0  
6. Any prior exposure to ibalizumab (formerly TNX -355 and Hu5A8)  
7. Any vaccination within 7 days before Day 0  
8. Any female patient who is pregnant, intends to become pregnant, or is currently 
breastfe eding  
9. Any current alcohol or illicit drug use that, in the investigator’s opinion, will interfere with 
the patient’s ability to comply with the study schedule and protocol evaluations  
10. Any previous clinically significant allergy or hypersensitivity to any excipient in the 
ibalizumab formulation  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  55    11. Any radiation therapy during the 28 days before first administration of investigational 
medication  on this study  
12. Any clinically significant Grade 3 or 4 laboratory abnormality according to the  DAIDS  
grading scale, except for the following asymptomatic Grade 3 events:  
– triglyceride elevation  
– total cholesterol elevation  
 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  56    5.3 Patient  Withdrawal and Discontinuation  
5.3.1  Reasons for Withdrawal  
A patient may be  withdraw n from the study if the patient : 
 
◼ Withdraws consent to participate  or requests an early discontinuation  at any time during 
the study  
◼ Is in violation of the protocol  
◼ Becomes pregnant during the study ( see Section 8.7  for a de scription of procedures to 
be followed in case of pregnancy)  
◼ Experiences virologic failure  
◼ Experiences a treatment -related serious or intolerable AE(s)  (according to DAIDS 
criteria, see Appendix B ) 
◼ Experiences toxicity, defined as two consecutive laboratory result s, at least 14 days 
apart,  with a CD4+ cell count below 200 cells/mm3 that also represents a 5 0% reduction 
from the baseline CD4+ cell count  
The study treatment should be discontinued for al l Grade 3 or 4 treatment -related abnormalities, as 
defined in Appendix B . Treatment -emergent Grade 3 or Grade 4 lab abnormalities should be 
retested  within 72 hours. Any patient  with a Grade 3  or Grade 4  lab abnormality that resolves before 
the next scheduled dose may have the study drug reinstituted. If a patient  develops a  persistent 
Grade  3 or Grade 4 treatment -emergent laboratory abnormality, excluding triglycerides and 
cholesterol,  that does not reso lve prior to the next scheduled study drug administration , study drug 
may be discontinued.  
 
A patient experiencing one or more treatment -emergent SAEs will receive treatment and follow -up 
evaluations by the Principal Investigator, or they will be referred to another appropriate physician 
for treatment and follow -up. Withdrawal from the study will be at the discretion of the Principal 
Investigator /Sponsor . 
 
The investigator will also withdraw a patient if the Sponsor or local regulatory agency (e .g., FDA) 
terminates the study. Upon occurrence of a n SAE, the Principal Investigator will notify the Sponsor 
or designee  of these events via the SAE hotline. If a patient is discontinued because of an AE, the 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  57    event will be followed until satisfactory resolution or until the Principal Investigator deems the event 
to be chronic or the patient to be stable.  
 
 
5.3.2  Handling Withdrawals and Discontinuations  
Patient s are free to withdraw from the study at any time u pon request. Patient  participation in the 
trial may be stopped at any time at the discretion of the investigator or at the request of the Sponsor 
or designee . At the time of withdrawal  or discontinuation , the investigator will assess the best 
options for t reatment and discuss these options with the patient.  
 
When a patient  withdraw s or is discontinued from the study , the reason(s) for withdrawal or 
discontinuation will be recorded by the investigator. Whenever possible, all patient s who withdraw , 
or are discontinued from the study prematurely , will undergo all Early Withdrawal  procedures as 
described in the Schedule of Events  in Section 3.4 . Patient s who fail to return for final assessments 
will be contacted by the site personnel in an attempt to have the patients comply with the protocol. 
A minimum of  two documented phone calls should be made over the course of at least  2 weeks. If 
the site personnel receive no response, they should send a certified letter requesting that the patient  
contact the site regardi ng their status in the study. If the patient  does not respond at this point, the 
date the certified letter was mailed will be considered the date of study withdrawal.  
 
In the event of a patient  death during the study, the date of death (as listed on the de ath certificate) 
will be used for the date of study discontinuation.  
 
It is vital to obtain follow -up data on any patient  withdrawn because of an AE or SAE. In such 
cases, the patient  will be followed to satisfactory resolution or until the Principal Investigator deems 
the event to be chronic or the patient  to be stable. In any case, every effort must be made to 
undertake protocol -specified safety follow -up procedures.  
 
 
5.3.3  Sponsor or Regulatory Agency Termination of Study  
Although the Sponsor intends to complete the study, the right is reserved to discontinue the study at 
any time for clinical or administrative reasons, upon commercial availability of ibalizumab, or if 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  58    requi red by the local regulatory authority (e .g., FDA).  If the Sponsor discontinues the study, the 
FDA will be notified promptly.  
 
 
6. Study Visits  
 
6.1 Cohort 1: 800 mg Every 2 Wee ks 
Since there are no laboratory parameters required for entry into Cohort 1 of this study, Screening  
procedures  and Day 0  procedures  are scheduled for the same day . Patients who qualify for entry into 
Cohort 1 of this study who are currently receiving 800 mg ibalizumab every 2 weeks will have  
physical and laboratory measures  performe d and receive the first on -study dose of ibalizumab  at 
Screening/Day 0 as specified in the Schedule of Events  (see Table 3 -1). These p atient s will return to 
the clinic on Day 14 and every  2 weeks thereafter through the remainder of participation in the 
study  for study drug administration  (800 mg)  and effectiveness  and safety evaluations.  Patients who 
are discontinued or who withdraw from the study prematurely  will be asked to return for an Early 
Withdrawal visit to have all assessmen ts detailed in the Schedule of Events for that visit performed . 
 
 
6.1.1 Screening/Day 0  
Screening and Day 0 (first on -study administration of ibalizumab) are scheduled for the same day. At 
this visit, study information will be reviewed and discussed, and t he informed consent form will be 
reviewed and signed by the participant. No procedures, other than a preliminary verbal assessment 
of eligibility by review of inclusion/exclusion criteria, may be done before the informed consent 
process is complete. Once i nformed consent has been obtained and documented, the following 
procedures may be completed  (pre-infusion) : 
 
◼ Record demographics, medical history (general and HIV), and the patient’s height  
◼ Record all prior ART exposure; record all other medications taken within the last 30 
days 
◼ Record results of a complete physical examination  
◼ Record vital sign measurements  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  59    ◼ Record the patient’s weight  
◼ Record all AEs that begin after the patient has signed the informed consent ( see Sectio n 
8.1 for definitions)  
◼ Collect blood and urine for  the following laboratory samples:  
– Hepatitis serology and C -reactive protein  
– Clinical laboratory assessments (serum chemistry, hematology, and urinalysis; see 
Section 7.2.2  for a complete list of parameters)  
– Archive sample  
– Serum pregnancy test in females of childbearing potential and a follicle -
stimulating hormone (FSH) test in postmenopausal females  
– HIV-1 RNA (viral load)  
– HIV-1 viral resistance sample (will be stored for later use if needed)  
– CD4+ cell count  (within 1 hour before the start of the infusion)  
– Immunogenicity of ibalizumab  
After the preceding procedures are completed, site personnel will undertake the following (infusion 
and post -infusion):  
 
◼ Administer study medication  (800 mg)  
◼ Record vital sign measurements after the completion of the infusion and observe the 
patient for at least 15 minutes  
◼ Record AEs  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  60      
6.1.2  Events for Day 14  (±1 day)  and Weeks 4, 6 , 8, 10, 14, 16, 18, 20, 
22, 26, 28, 30, 32, 34, 38, 40, 42, 44 , 46, 50, 52, 54, 56, 58, 62, 
64, 66, 68, 70, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94,  98, 100, 
102, 104, 106, 110, 112, 114, 116, 118, 122, 124, 126, 128, 130, 
134, 136, 138, 140, and 142  (±2 days)  
The following will be completed before  study drug administration:  
 
◼ Record vital sign measurements  
◼ Record AEs and concomitant medications  
◼ Assess adherence to the OBR (Weeks 4 , 8, and 84  only)  
◼ Collect urine sample for the following:  
Urine pregnancy test for females of childbearing potential (Weeks 4, 8, 16, 20, 28, 32, 
40, 44, 52, 56, 64, 68, 76, 80, 84, 88, 92 , 100, 104, 112, 116, 124, 128, 136, and 140  only)  
Site personnel will undertake the following after administration of study drug (800 mg):  
 
◼ Record vital sign measurements after completion of infusion and observe patient for at 
least 15 minutes  
◼ Record AEs  
 
6.1.3  Events for Weeks 12, 24, 36 , 48, 60, 72,  96, 108, 120, 132, 
144/EOS and 1 50/Follow -up (±2 days)  
The following will be completed before  study drug administration:  
 
◼ Record results of physical examination ( complete exam at Weeks 24 , 48, 72, 96, 120, 
144, and 1 50; abbreviated exam at Weeks 12 , 36, and 60) 
◼ Record the patient’s weight  (Weeks 12, 24, 36, 48 , 60, 72, 96, 120, 144 and 150 only)  
◼ Record vital sign measurements  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  61    ◼ Record  AEs and concomitant medications  
◼ Assess adherence to the OBR  
◼ Collect blood and/or urine samples for the following:  
– Hepatitis serology and C -reactive protein (Weeks 24 , 48,  96, and 150 only)  
– Clinical laboratory assessments (serum chemistry, hematology, and urinalysis; See 
Section 7.2.2  for a complete list of parameters)   (Weeks 12, 24, 36, 48, 60, 72, 96, 
120, and 150  only) 
– Archive sample  (Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, and 150  only) 
– Pregnancy test for females of childbearing potential ( urine at Weeks 12 , 36, 60, 
108, 120, 132, 144, and 150  only); serum at Week s 24, 48, 72, and 96 only) 
– HIV-1 RNA (viral load)   
– HIV-1 vira l resistance sample  (will be stored for later use if needed)   
– CD4+ cell count (within 1 hour before the start of the infusion)  
– Immunogenicity of ibalizumab (Week s 24, 48, 72, 96 , 120, 144, and 1 50 only).  
Site personnel will undertake the following after administration of study drug  (800 mg)  (not done at 
Week 1 50/Follow -up): 
 
◼ Record vital sign measurements after completion of infusion and observe patient for at 
least 15 minutes  
◼ Record AEs  
 
6.2 Cohort 1: 2,000  mg Every 4 Weeks  
Since there are no laboratory parameters required for entry into Cohort 1 of this study, Screening 
procedures and Day 0 procedures are scheduled for the same day. Patients who qualify for entry into 
Cohort 1 of this study who are currently receiving 2,000  mg ibalizumab every 4 weeks will have 
physical and laboratory measures  performed  and will receive the first on -study dose of ibalizumab at 
Screening/Day 0 , as specified in the Schedule of Events (see Table 3 -3). These patients will return to 
the clinic at Week 4  and every 4 weeks thereafter through the remainder of participation in the study 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  62    for study drug administration (2,000  mg) and effectiveness and safety evaluations. Patients who are 
discontinued or who withdraw from the study prematurely will be aske d to return for an Early 
Withdrawal visit to have all assessments detailed in the Schedule of Events  for that visit  performed.  
 
 
6.2.1  Screening/Day 0  
Screening and Day 0 (first on -study administration of ibalizumab) are scheduled for the same day. At 
this visit, study information will be reviewed and discussed, and the participant will review and sign 
the informed consent form. No procedures, other than a preliminary verbal assessment of eligibility 
by review of inclusion/exclusion criteria, may be done be fore the informed consent process is 
complete. Once informed consent has been obtained and documented, the following procedures 
may be completed (pre -infusion):  
 
◼ Record demographics, medical history (general and HIV), and the patient’s height  
◼ Record all pr ior ART exposure; record all other medications taken within the last 30 
days 
◼ Record results of a complete physical examination  
◼ Record vital sign measurements  
◼ Record the patient’s weight  
◼ Record AEs  that begin after the patient signs the informed consent ( see Section 8.1  for 
definitions)  
◼ Collect blood and urine for  the following laboratory samples:  
– Hepatitis serology and C -reactive protein  
– Clinical laboratory assessments (serum chemistry, hematology, and urinalysis; see 
Section 7.2.2  for a complete list of parameters)  
– Archive sample  
– Serum pregnancy test in females of childbearing potential and a n FSH test in 
postmenopausal females  
– HIV-1 RNA (viral load)  
– HIV-1 viral resistance sample (will be stored for later use if needed)  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  63    – CD4+ cell count (within 1 hour before the start of the infusion)  
– Immunogenicity  of ibalizumab  
After the preceding procedures are completed, site personnel will undertake the following (infusion 
and post -infusion):  
 
◼ Administer study medication ( 2,000  mg) 
◼ Record vital sign measurements after the completion of the infusion and observe the 
patient for at least 15 minutes  
◼ Record AEs  
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  64    6.2.2 Events for Weeks 4, 8, 16, 20, 28, 32, 40, 4 4, 52, 56, 64, 68, 76, 
80, 84, 88, 92 , 100, 104, 112, 116, 124, 128, 136, and 140  (±2 
days)  
The following will be completed before  study drug administration:  
 
◼ Assess adherence to the OBR (Weeks 4 , 8, and 84 only)  
◼ Record vital measurements  
◼ Record AEs and concomita nt medications  
◼ Collect urine sample for the following:  
Urine pregnancy test for females of childbearing potential  
Site personnel will undertake the following after administration of study drug ( 2,000  mg): 
 
◼ Record vital sign measurements after completion of  infusion and observe patient for at 
least 15 minutes  
◼ Record AEs  
 
6.2.3 Events for Weeks 12, 24, 36 , 48, 60, 72, 96, 108, 120, 132, , 
144/EOS, and 1 50/Follow -up (±2 days)  
The following will be completed before  study drug administration:  
 
◼ Record results of physical examination ( complete exam at Weeks 24 , 48, 72, 96 , 120, 
144, and 1 50 only; abbreviated exam at Weeks 12 , 36, and 60 only) 
◼ Record the patient’s weight   (Weeks 12, 24, 36, 48, 60, 72, 96, 120, 144, and 150  only) 
◼ Record vital sign measurements  
◼ Record  AEs and concomitant medications  
◼ Assess adherence to the OBR   
◼ Collect blood and/or urine samples for the following:  
– Hepatitis serology and C -reactive protein (Weeks 24 , 48, 7296 , and 150  only)  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  65    – Clinical laboratory assessments (serum chemi stry, hematology, and urinalysis; See 
Section 7.2.2  for a complete list of parameters)  (Weeks 12, 24, 36, 48, 60, 72, 96, 
120, and 150 only) 
– Archive sample  (Weeks 12, 24, 3 6, 48, 60, 72, 96, 120, 144, and 150  only) 
– Pregnancy test for females of childbearing potential ( urine at Weeks 12 , 36, 60, 
108, 120, 132, 140, 144, and 150  only; serum at Week s 24, 48, 72, and 96 only   ) 
– HIV-1 RNA (viral load)  
– HIV-1 viral resistance sample  (will be stored for later use if needed)   
– CD4+ cell count (within 1 hour before the start of the infusion)  
– Immunogenicity of ibalizumab (Week s 24, 48, 72, 96, 120, 144, and 150 only)  
Site personnel will undertake the following after administration of stud y drug  (2,000  mg) (not done 
at Week 1 50/Follow -up): 
 
◼ Record vital sign measurements after completion of infusion and observe patient for at 
least 15 minutes  
◼ Record AEs  
 
6.3 Cohort 2  
Patients will complete all Screening procedures during the 6 weeks before Day 0/Baseline. 
Successful Screening results will allow the patients to proceed to the Day 0/Baseli ne visit, where 
they will initiate the selected  OBR in addition to undergoing physical and laboratory measures as 
specified in the Schedule of Events (see Table 3 -5). At this visit , patients will also receive the loading 
dose of the study medication  (2,000  mg). Patients will return to the clinic on Day  7 for effectiveness 
and safety evaluations and on  Day 14 and every 2 weeks thereafter through the remainder of 
participation in the study for study drug administration  (800 mg)  and effectiveness and safety 
evaluations. Patients who are discontinued or who  withdraw from the study prematurely will be 
asked to return for an Early Withdrawal visit to complete  all assessments for that visit, as detailed in 
the Schedule of Events.  
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  66    6.3.1  Screening (Weeks -6 to -1) 
Screening will begin  up to 6 weeks before Day 0 . During Screening , study information will be 
reviewed and discussed , and the participant will review and sign the informed consent form. No 
procedures, other than a preliminary verbal assessment of eligibility by review of inclusion/excl usion 
criteria, may be done before the infor med consent process is complete . Once informed consent has 
been obtained  and documented , the following Screening procedures may be completed:  
 
◼ Record demographic s, medical history  (general and HIV) , and the patie nt’s height  
◼ Record all prior ART exposure; record all other medications  taken within the last 30 
days 
◼ Obtain documentation of HIV -1 infection ; if official, signed, written  documentation  is 
unavailable , then collect a sample for HIV antibody test ing as indicated below : 
– Obtain documentation of viral resistance, if available (within 6 months of 
Screening) , and select an OBR  
– Record results of a complete physical examination  
– Record vital sign  measurement s 
– Record the patient’s weight  
– Record only study -related AEs, which begin once the patient signs the informed 
consent ( see Section 8.1  for definitions)  
◼ Collect blood and urine for  the following laboratory samples:  
– Hepatitis serology and C -reactive protein  
– Clinical laboratory assessments (serum chemistry, hematology, and urinalysis; see 
Section 7.2.2 for a complete list of parameters)  
– Serum pregnancy test in females  of childbearing potential  and an FSH test in 
postmenopausal females  
– HIV-1 RNA (viral load) 
– HIV-1 antibody level, if documentation of HIV -1 infection is not provided  as 
indicated above  
– HIV-1 viral resistance sample (will be stored for later use if needed)  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  67    – CD4+ cell count  
If a patient fails Screening, the y may be re -screened one time.  
 
 
6.3.2 Day 0 /Baseline  
The Day 0 /Baseline  visit may take place at any point during the 4 weeks following the Screening 
Visit. At this visit , patients will receive the first study drug infusion: a loading dose of 2,000  mg. All 
patients must be observed for 1 hour after completion of study drug administration at Baseline. If 
the patient does not experience an AE(s) related to the infusion (local or systemic) through and 
including the second infusion on Day 14, then the ob servation time can be reduced to 15 minutes 
thereafter. Patients will return to the site every 2 weeks (±2 days) for the remainder of the study to 
receive additional study drug and for effectiveness  and safety evaluations.  At this visit, the following 
will be completed before  study drug administration:  
 
◼ Record any changes to  ART; record all other medications taken within the 30 days 
before  the baseline visit  
◼ Record results of a complete physical examination  
◼ Record vital sign  measurement s 
◼ Record the patient ’s weight  
◼ Record  only study -related AEs 
◼ Collect blood and urine samples for the following:  
– Clinical laboratory assessments (serum chemistry, hematology, and urinalysis; see 
Section  7.2.2 for a complete list of parameters)  
– Archive sample  
– Urine pregnancy test  for females of childbearing potential  
– HIV-1 RNA (viral load)  
– HIV-1 viral resistance sample (will be stored for later use if needed)  
– CD4+ cell count  (within 1 hour before the start of t he infusion)  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  68    – Immun ogenicity  of ibalizumab  
The patient will also initiate the selected OBR on this day, either at home or in the clinic with site 
personnel supervision.  
After the preceding procedures are completed, site personnel will undertake the followin g (infusion 
and post -infusion):  
 
◼ Administer loading dose of study medication  (2,000  mg) 
◼ Record vital sign  measurement s after the completion of the infusion  and observe the 
patient for at least 1 hour  
◼ Record all AEs 
 
6.3.3  Events for Day 7 (±1 day) 
Day 7 serves as the time point at which the antiviral activity of ibalizumab  will be assessed to address 
the primary effectiveness objective of the study.  
 
Site personnel will undertake the following:  
 
◼ Assess adherence to the OBR  
◼ Record results of abbreviated physical examination  
◼ Record vital sign measurements, AEs, and concomitant medications  
◼ Collect blood and urine samples for the following:  
– Clinical laboratory assessments (serum chemistry, hematology, and urinalysis; see 
Section 7.2.2  for a complete list of parameters)  
– Archive sample  
– HIV-1 RNA (viral load) 
– HIV-1 viral resistance sample (will be stored for later use if needed)  
– CD4+ cell count   
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  69    6.3.4  Events for Day 14 (±1 day), and Weeks 4, 6, 8, 10, 14 , 16, 18, 20, 
22, 26, 30, 32, 34, 38, 40, 42, 44, 46, 50, 52, 54, 56, 58, 62, 64, 
66, 68, 70, 74, 76, 78, 80, 82, 86, 88, 90, 92, 94 , 98, 100, 102, 
104, 106, 110, 112, 114, 116, 118, 122, 124, 126, 128, 130, 134, 
136, 138, 140, and 142  (±2 days)  
The following will be completed before  study drug administration:  
 
◼ Record results of physical examination ( complete exam at Week 4  only, abbreviated 
exam at Week s 20, 32, and 40  only)  
◼ Record the patient’s weight (Weeks 4, 20, 32, and 40 only)  
◼ Record vital  sign measurements  
◼ Record AEs and concomitant medications  
◼ Assess adherence to the OBR (Weeks 4 , 8, 20, 32 , and 40 only)  
◼ Collect urine and perform pregnancy test for females of childbearing potential (Weeks 
4, 8, 16, 20, 32, 40 , 44, 52, 56, 64, 68, 76, 80, 88, 92 , 100, 104, 112, 116, 124, 128, 136, 
and 140  only)   
◼ Collect blood samples for the following:  
– HIV-1 RNA (viral load)  ( Day 14, and Weeks 4, 6, 8, 16, and 20  only) 
– HIV-1 viral resistance sample (will be stored for later use if needed)  (Day 14 , and 
Week s 4, 6, 8, 16, and 20  only)   
– CD4+ cell count (Day 14 ,   and Weeks 4, 6, 8, 16, and 20 only)  
Site personnel will undertake the following after administration of study drug  (800 mg) : 
 
◼ Record vital sign measurements after completion of infusion and observe patient for at 
least 1 hour; i f the patient did not experience an AE(s) related to the infusion (local or 
systemic) through and including the infusion on Day 14, then the observation time can 
be reduced to 15 minutes  
◼ Record AEs   
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  70    6.3.5  Events for Weeks 12 , 24, 48, 60, 72, 84, 96 , 108, 120, 132, and 
144/EOS  (±2 days)  
Site personnel will undertake the following before  administration of study drug:  
 
◼ Record results of physical examination ( complete exam at Week  24, 48, 72 , 96, 120, and 
144 only ; abbreviated exam at Weeks 12, 60, and 84  only) 
◼ Record the patient’s weight  (Weeks 12, 24, 48, 60, 72, 84, 96, 120, and 144  only)  
◼ Record vital sign measurements  
◼ Record AEs and concomitant medications  
◼ Assess adherence to the OBR   
◼ Collect blood an d/or urine samples for the following:  
– Hepatitis serology and C -reactive protein (Weeks 24, 48, and 96, only)  
– Clinical laboratory assessments (serum chemistry, hematology, and urinalysis; see 
Section 7.2.2  for a complete list of parameters)  (Weeks 12, 24, 4 8, 60, 72, 84, 96, 
and 120  only) 
– Archive sample   (Weeks 12, 24, 48, 60, 72, 84, 96, 120, and 144  only)  
– Pregnancy test for females of childbearing potential ( serum at Week s 24, 48, 72, 
and 96  only; urine at all other listed weeks)  
– HIV-1 RNA (viral load)  
– HIV-1 viral resistance sample  (will be stored for later use if needed)   
–  
– CD4+ cell count (within 1 hour before the start of the infusion)  
– Immunogenicity  of ibalizumab  (Week s 24, 48, 72, 96, , 120, and 144 only)  
Site personnel will undertake the following after administration of study drug  (800 mg) : 
 
◼ Record vital sign measurements after completion of infusion and observe patient for at 
least 1 hour; i f the patient did not experience an AE(s) related to the infusion (local or 
systemic)  through and including the second infusion on Day 14, then the observation 
time can be reduced to 15 minutes  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  71    ◼ Record AEs  
 
6.3.6  Events for Weeks 28 and 36 (±2 days)   
The following will be completed before  study drug administratio n: 
 
◼ Record the patient’s weight (Week 36 only)  
◼ Record vital sign measurements  
◼ Record AEs and concomitant medications  
◼ Collect blood and/or urine samples for the following:  
– Clinical laboratory assessments (serum chemistry, hematology, and urinalysis; see 
Section 7.2.2  for a complete list of parameters)  
– Archive sample  
– Urine pregnancy test for females of childbearing potential  
– HIV-1 RNA (viral load)  
– HIV-1 viral resistance sample  (will be stored for later use if ne eded)  
– CD4+ cell count (within 1 hour before the start of the infusion)  
Site personnel will undertake the following after administration of study drug (800 mg):  
 
◼ Record vital sign measurements after completion of infusion and observe patient for at 
least 1 hour; i f the patient did not experience an AE(s) related to the infusion (local or 
systemic) through and including the infusion on Day 14, then the observation time can 
be reduced to 15 minutes  
◼ Record AEs  
 
6.3.7  Events for Week 150/Follow -up Visit (± 2 days)  (Study drug is not 
administered at this visit)  
The following procedures will be completed  at the Week 102/Follow -up visit: 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  72    ◼ Record results of  a complete physical examination  
◼ Record the patient’s weight  
◼ Record vital sign measurements;  
◼ Record AEs and concomitant medications  
◼ Assess adherence to the OBR  
◼ Collect blood and/or urine samples for the following:  
– Hepatitis serology and C -reactive protein  
– Clinical laboratory assessments (serum chemistry, hematology, and urinalysis; see 
Section 7.2.2  for a complete list of parameters)  
– Archive sample  
– Urine pregnancy test for females  of childbearing potential  
– HIV-1 RNA (viral load) 
– HIV-1 viral resistance sample (will be stored for later use i f needed)  
– CD4+ cell count  
– Immunogenicity  of ibalizumab  
 
6.4 Early Withdrawal Procedures  
Patient s who withdraw from the study at any time  before Week 96/EOS  will be asked to complete 
all Early Withdrawal  procedures to ensure safety and collect as much effectiveness  data as possible .  
 
The following procedures will be completed at the Early Withdrawal visit (study drug is not 
administered at Early Withdrawal) : 
 
◼ Record results of a complete physical examination  
◼ Record the patient’s weight  
◼ Record vital sign measurements  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  73    ◼ Record AEs and concomitant medications  
◼ Assess adherence to the OBR  
◼ Collect blood and/or urine samples for the following:  
– Hepatitis serology and C -reactive protein  
– Clinical laboratory assessments (serum chemistry, hematology, and uri nalysis; see 
Section 7.2.2  for a complete list of parameters)  
– Archive sample  
– Serum pregnancy test for females of childbearing potential  
– HIV-1 RNA (viral load)  
– HIV-1 viral resistance sample (will be stored for l ater use if needed)  
– CD4+ cell count  
– Immunogenicity of ibalizumab  
 
6.5 Unscheduled Visits  
Unscheduled visits are allowed for the following reasons:  
 
◼ To perform a confirmatory plasma viral load determination  
◼ To perform confirmatory laboratory testing for cli nically abnormal values  
◼ Any time the investigator feels that they are  clinically required for safety reasons related 
to the patient ’s participation in this trial  
Findings during these unscheduled visits must be reported in the EDC  system under the 
unschedu led visit section.  
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  74    7. Study Assessments  
 
A central laboratory will analyze all blood and urine samples with the exception of the HIV -1 
resistance test ing and immunogenicity testing , which will be undertaken by appropriate specialty 
contract laboratories . Urine samples will be analyzed at the site; if abnormal results are obtained for 
a patient, a urine sample will be sent to the central laboratory for microscopic evaluation.  
 
The following assessments will be conducted at the times indicated in the Schedule of Events 
(Tables 3 -1 through  3-6). 
 
 
7.1 Activities to Be Completed  
7.1.1  Demographic Data, Medical History, and Concomitant Medications  
Demographic data, a complete medical history (per patient  report), and documentation of prior 
medications will be collected at Screening ; information about recent or concomitant medications will 
be obtained at each visit. If the patient is enrolling into Cohort 2, t he patient  will supply official 
written documen tation of HIV -1 infection at Screening , if possible. Otherwise, a sample for a n 
HIV-1 antibody test must be collected as part of the Screening procedures.  
 
 
7.1.2  Complete Physical Examination  
A complete physical examination will include the following orga n or body system assessments: head, 
eyes, ears, nose, throat, musculoskeletal, cardiovascular, lymphatic, respiratory, gastrointestinal, skin, 
neurological, and other findings of note. Height and weight will be measured at Screening , and 
weight only will b e measured at other times specified.  
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  75    7.1.3  Abbreviated Physical Examination  
An abbreviated physical examination will be limited to lymph nodes, respiratory and cardiovascular 
systems, abdomen, extremities, and nervous system and assessment of any specifi c signs and 
symptoms that the patient  reports.  
 
 
7.1.4  Vital Sign Measurements  
Vital sign measurements will include the patient ’s heart rate (beats/minute taken for  1 full minute), 
blood pressure (mm  Hg), respiratory rate (breaths/minute taken for  1 full m inute), and oral 
temperature (ºC). Measurements will be taken within 1 hour before the start of the infusion and 15 
minutes after the end of the infusion. Blood pressure and heart rate measurements will be obtained 
after the patient  has been seated for at least  5 minutes. Ideally, each patient ’s blood pressure should 
be measured using the same arm and the same size cuff at each visit.  
 
 
7.2 Blood and Urine S amples  
7.2.1  Hepatitis Serology and C -Reactive Protein  
Patient s will be screened for hepatitis B (surface antigen) and hepatitis C to determine their hepatitis 
status.  
 
Blood samples will be taken for the analysis of C -reactive protein, which is an inflammatory marker 
whose concentration increases with acute or chronic inflammation.  
 
 
7.2.2  Clinical Laboratory Parameters  
Collection of blood and urine samples for clinical laboratory assessments will be part of a normal 
safety profile assessment for th e study  patients. Patients need not fast before blood sampling.  
Samples will be processed using standard procedures as described in the laboratory procedures 
manual and will be analyzed by a central laboratory unless otherwise noted.  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  76    The samples wil l be a nalyzed for the following:  
 
◼ Hematology:  complete white blood cell count with differential, hemoglobin, 
hematocrit, and platelets  
◼ Serum chemistry profile:  albumin, alkaline phosphatase, alanine  aminotransferase 
(ALT), amylase, aspartate aminotransferase (AST), blood urea nitrogen, calcium, 
chloride, creatine phosphokinase, creatinine, direct bilirubin, gamma  glutamyl 
transferase, glucose, lactate dehydrogenase, lipase, lipid profile (total cholesterol, high -
density lipoprotein, low -density lipoprotein, and t riglycerides), magnesium, phosphorus, 
potassium, sodium, total bilirubin, total protein, and uric acid  
◼ Urinalysis:  visual inspection for appearance and dipstick assessment for color, pH, 
specific gravity, ketones, protein, glucose, bilirubin, nitrite, urob ilinogen, and leukocyte 
esterase  
The urinalysis will be performed at the site by qualified personnel. If the results of  the urinalysis are 
abnormal, a urine sample will be sent to the central laboratory for microscopic evaluation. Samples 
will be processed as described in the laboratory procedures manual before being sent to the central 
laboratory  for evaluation . 
 
Tests with Grade 3 or Grade 4 abnormal results should be repeated within 72 hours  of the site 
becoming aware of the abnormal value(s). See Appendix B  for details  and definitions of toxicities . 
The Principal Investigator should discuss any Grade 3 or 4 abnormal laborat ory results with the 
medical monitor /Sponsor for appropriate patient disposition, including potential withdrawal from 
the study (see Section 5. 3.1 for additional information).  Per Section 5. 3.1, the study treatment should  
be stopped for all Grade 3 or 4 treatment -related laboratory abnormalities, as defined in Appendix 
B. Any patient with a Grade 3 or Grade 4 laboratory  abnormality that resolves b efore the next 
scheduled dose may have the study drug reinstituted. If a patient develops a persistent Grade 3 or 
Grade 4 treatment -emergent laboratory abnormality, excluding triglycerides and cholesterol, that 
does not resolve prior to the next scheduled study drug administration , study drug  may be 
discontinued . Patients with Grade 3 or 4 triglyceride and/or cholesterol elevations are allowed to 
continue to receive study drug . 
 
 
7.2.3  Archive Sample  
A separate blood sample will be taken and stored for poss ible research use.  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  77     
 
7.2.4  Serum Follicle -Stimulating Hormone Testing  
A serum FSH test will be performed on postmenopausal females at Screening  (see Section 8.7 ). The 
level of FSH should exceed 35 IU/L for the patient  to be considered postmenopausal. If the patient  
does not meet this criterion, she must agree to use proper birth control precautions as described in 
Section 8.7  and mus t have serum and urine pregnancy tests throughout the protocol at times 
specified in the Schedule of Events.  
 
 
7.2.5  Pregnancy Testing  
A serum pregnancy test will be performed at Screening , EOS, Early Withdrawal and other defined 
visits for all females of childbearing potential. A urine pregnancy test will be performed at other 
defined study visits to confirm that a female has not become pregnant during the study. These tests 
are performed for the protec tion and safety of the fetus , as the risk to the fetus is unknown . Any 
patient  who becomes pregnant during the study will be withdrawn from the study. See Section 8.7  
for a description of procedures to be followed in case o f pregnancy.  
 
 
7.2.6  HIV-1 RNA Level  
Blood samples for viral load will be used to determine the effectiveness of the study regimens  and 
should be drawn before infusion during visits that include an infusion.  
 
 
7.2.7  HIV-1 Viral Resistance Testing  
Blood samples for HIV -1 viral resistance testing  should be collected before  the start of the infusion 
at the indicated visits. Viral resistance testing will include assessments of reverse transcriptase, 
protease, integrase and envelope genes , and chemokine  coreceptor utilization; the samples will be 
collected and stored, and testing will only be performed for patients who experience virologic failure 
while on the study .  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  78    Collected and stored samples may also be used for the TrofileTM Assay, a blood test th at identifies 
the tropism of a patient ’s HIV strain (i .e., R5, X4, or a combination). The results show whether the 
patient is infected with the virus that enters cells using the R5 co -receptor, the X4 co -receptor, or 
both.  
 
 
7.2.8  CD4+ Cell Count  
Blood sam ples for CD4+ cell count  will be collected over the course of the study to determine how 
well the immune system is functioning. In most patient s infected with HIV, an increase in the 
number of CD4+ cells is a n indicator of the effectiveness of antiretroviral medication.  
 
If a patient experiences toxicity, defined as two consecutive laboratory results, at least 14 days apart, 
with a CD4+ cell count below 200 cells/mm3 that also represents a 50% reduction from th e baseline 
CD4+ cell count, the patient will be discontinued from the study.  
 
 
7.2.9 Immunogenicity of Ibalizumab  
Blood samples will be collected to test for the development of antibodies against ibalizumab  at Day 
0, EOS , Early Withdrawal , and other define d visits . Samples will be collected  prior to ibalizumab  
infusion  if an infusion is scheduled for that visit.  The incidence of anti -ibalizumab  antibody 
production will be determined using a validated enzyme -linked immunosorbent assay (ELISA) that 
has been validated for the detection of anti -ibalizumab  antibodies in human serum even if circulating 
drug is present.  Additional  samples may be collected  when clinical observations suggest the 
possibility of a clinically significant anti -ibalizumab  immune res ponse (e.g. , allergic response, serum 
sickness, low drug levels, and/or loss of virologic response).  
 
 
8. Adverse Events  
 
8.1 Definitions  
Per the FDA regulations in 21 CFR 312.32, the following definitions apply to this protocol:  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  79     
Adverse Events . An AE is defined as any untoward medical occurrence associated with the use of a 
drug in humans, whether or not considered drug related.  
 
Adverse Reaction.  Any AE caused by a drug.  
 
Treatment -Emergent AEs . A TEAE  is defined as any event not present before exposure to study 
drug or any event already present that worsens in either intensity or frequency following exposure to 
test medication.  
 
Serious Adverse Event  or Serious Suspected Adverse Reaction. An AE or suspected adverse 
reaction is considered ‘‘serious’’ if, in the view of either the investigator or Sponsor, it results in any 
of the following outcomes: death, a life -threatening AE, inpatient hospitalization or prolongation of 
existing hospitalization , a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions, or a congenital anomaly/birth defect. Important medical events that 
may not result in death, be life -threatening, or require hospitalization  may be considered serious 
when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may 
require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
 
Suspected Adverse Reaction . A suspected adverse reaction means any AE for which there is a 
reasonable possibility that the drug caused the AE. For the purposes of IND safety reporting, 
“reasonable possibility” means there is evidence to suggest a causal relationship between the drug 
and the AE.  
 
Unexpected Adverse Event or Unexpected Adverse Reaction . This term refers to a n AE or 
adverse reaction that is not listed in the investigator’s brochure or is not listed at the specificity or 
severity that has been observed.  
 
 
8.2 Eliciting Adver se Event Information  
At every study visit, patients will be asked a standard, nondirective question, such as “How have you 
been feeling since your last visit?” to elicit any medically related changes in their well -being. They 
will also be asked if they hav e been hospitalized, had any accidents, used any new medications, or 
changed concomitant medication regimens (both prescription and over -the-counter medications).  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  80     
In addition to patient self -report, AEs will be documented from clinically significant findi ngs 
resulting from abnormal laboratory test values, physical examination findings, or other documents 
that are relevant to patient safety.  
 
 
8.3 Reporting Adverse Events  
The investigator is responsible for reporting to the Sponsor or designee all AEs that  are observed or 
reported by the patient during the study (from the time the patient signs informed consent until 30 
days after the last dose of study medication is given), regardless of their relationship to study drug or 
their clinical significance. Pati ents will be instructed to contact study site personnel at any time after 
informed consent if any symptoms develop.  
 
To ensure compliance with FDA regulations (21 CR 312.64), site investigators must immediately 
report to the Sponsor all AEs that meet the S AE criteria, regardless of presumed relationship to the 
investigational agent. The Sponsor will carefully review the SAE information to monitor the 
investigational drug’s toxicity profile and patient safety.  If any event meets the FDA’s reporting 
criteria,  it will be submitted to the FDA as an IND Safety Report (21 CFR 312.32).  
 
Recording of AEs will begin after study drug is first administered . Any untoward medical condition 
that occurs after the informed consent is signed but before the first administration of the study drug 
will be recorded as medical history, unless it is related to a study procedure. AE s will be recorded 
from the first dose of study medication and until 30 days after the last dose of study medication, 
regardless of its relationship to study drug . AEs will be documented in the patient’s source 
documents and recorded in the AE section of the EDC system.  
 
All AEs reported or observed during the study must be recorded in detail in the AE section of the 
EDC system and followe d to a satisfactory resolution or until the Principal Investigator  deems the 
event to be chronic or the patient to be stable.  
 
Information to be collected includes the event  term, date of onset, date of resolution, Investigator -
specified assessment of seve rity and relationship to study drug, and seriousness, as well as any 
required treatment or evaluations and outcome.  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  81    Pre-existing conditions (present before the start of the AE collection period) are considered 
concurrent medical conditions and should NOT be recorded as AEs. However, if the pre-existing 
condition worsens in severity, the investigator must report i t as an AE.  
 
Each AE should be recorded to represent a single diagnosis. Accompanying signs (including 
abnormal laboratory values) or symptoms sho uld NOT be recorded as additional AEs. If a diagnosis 
is unknown, sign(s) or symptom(s) should be recorded as an AE(s). Changes in laboratory values are 
only considered to be AEs if they are judged to be clinically significant (i.e., if some action or 
intervention is required or if the investigator judges the change to be beyond the range of normal 
physiological fluctuation). If abnormal laboratory values are the result of pathology for which there 
is an overall diagnosis (e.g., increased creatinine in rena l failure), the diagnosis only should be 
recorded as an AE.  
 
Pre-planned procedures (surgeries or therapies) that were scheduled prior to the start of AE 
collection are not considered AEs. However, if a pre -planned procedure is performed early (e.g., as 
an emergency) due to a worsening of the pre -existing condition, the worsening of the condition 
should be captured as an AE. Elective procedures performed where there is no change in the 
patient’s medical condition should not be recorded as AEs, but should be  documented in the 
patient’s source documents.  
 
The Medical Dictionary for Regulatory Activities ( MedDRA ) and WHO Drug Dictionary 
(WHODD ) will be used to code all AEs and classify all medicines, respectively. All coding will be 
performed by Westat and will be reviewed and approved by the medical monitor.  
 
All AEs, whether serious or not, should be followed to a satisfactory resolution or until the Principal 
Investigator deems the event to be chronic or the patient to be stable and the AE is determined to 
be not clinically significant.  
 
 
8.4 Assessment of Causality  
The investigator’s assessment of an AE ’s relationship to study drug is part of the documentation 
process, but it is not a factor in determining what is or is not reported in the study. If there is any 
doubt as to whether a clinical observation is an AE, the event should be reported.  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  82    The relationship or association of the study drug in causing or contributing to the AE will be 
characterized by the investigator using the following classifications and  criteria:  
 
Unrelated . This relationship suggests that there is no association between the study drug and the 
reported event. To be deemed unrelated, an alternative etiology must be present.  
 
Possible . This relationship suggests that treatment with the study drug caused or cont ributed to the 
AE. That is, the event follows a reasonable temporal sequence from the time of drug administration 
and/or follows a known response pattern to the study drug, but could also have been produced by 
other factors.  
 
Probable . This relationship su ggests that a reasonable temporal sequence of the event with drug 
administration exists and —based upon the known pharmacological action of the drug, known or 
previously reported adverse reactions to the drug or class of drugs, or judgment based on the 
investigator’s clinical experience —the association of the event with study drug administration seems 
likely.  
 
Definite . This relationship suggests that a definite causal relationship exists between the drug 
administration and the AE and that other conditions (concurrent illness, progression/expression of 
disease state, or concurrent medication reaction) do not appear to exp lain the event.  
 
 
8.5 Assessment of Severity  
The intensity of the AE will be rated by the investigator as mild, moderate, severe, or potentially life -
threatening using the following criteria:  
 
Mild (Grade 1):  Symptoms causing no or minimal interference wit h usual social and functional 
activities.  
 
Moderate (Grade 2):  Symptoms causing greater than minimal interference with usual social and 
functional activities.  
 
Severe (Grade 3):  Symptoms causing inability to perform usual social and functional activities.  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  83    Potentially Life -Threatening (Grade 4):  Symptoms causing inability to perform basic self -care 
functions OR medical or operative intervention indicated to prevent permanent impairment, 
persistent disability, or death.  
 
Details for grading severity are give n in Appendix B . Changes in the severity of an AE should be 
documented to allow an assessment of the duration of the event at each level of intensity to be 
performed. AEs characterized as intermittent require documentation of onset and duration of each 
episode.  
 
 
8.6 Serious Adverse Event Reporting  
Any AE considered serious by the Principal Investigator according to the previously described 
criteria must be reported using the Westat SAE Report Form and submitted to the Westat 
Regulatory Affairs Department v ia fax or email within 24 hours  of the site becoming aware of the 
event. Site staff must alert Westat of incoming safety information via the Westat SAE Hotline, either 
prior to or immediately after faxing/emailing the SAE Form.  
 
SAE Hotline:   888-464-5246  
SAE Fax:  888-865-1983 
Email:   Regulatory@Westat.com  
 
SAE reports must be supported by source documents. Key information that must be supported by 
source documents includes:  
 
◼ Event term  
◼ Onset date  
◼ Event management  
◼ Relatedness of the event to the study drug  
◼ Changes in study drug dosage, including suspension or discontinuation  
◼ If judged not study drug -related, an alternate etiology  
◼ Resolution date  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  84    When reporting an SAE to Westat, a thorough summary of the event should be provided, including 
copies of related documentation. Before submission of these documents to Westat, all patient 
identifiers must be obliterated; the documents must be labeled only with the patient’s identification 
number to safeguard the patient’s privacy.  
 
Supplemental source d ocumentation related to the SAE may include:  
 
◼ Clinic and/or hospitalization records  
◼ Laboratory reports  
◼ Pathology reports  
◼ Surgical reports  
◼ Other test results, such as E CGs, x -rays, lumbar punctures, and computed tomography 
(CT) scans  
◼ Consult notes  
◼ Hospital admission and discharge summary  
◼ Death certificate  
◼ Autopsy report  
When an SAE results in hospitalization or prolongation of an existing hospitalization, a copy of the 
hospital admission and discharge summaries and any pertinent laboratory or diagnostic repo rts 
should be faxed to Westat as soon as they become available. Similarly, documentation of the cause 
of death (e.g., an autopsy report or death certificate) should be submitted to Westat when a death is 
reported.  
 
The investigator should report to Westat any change in the initial SAE Report information or 
additional information that becomes available after the initial SAE Report submission. Each follow -
up SAE Report should be numbered sequentially.  
 
The Sponsor or designee will notify the FDA and all parti cipating Principal Investigators in an IND 
safety report about potential serious risks, from clinical trials and any other source, no later than 15 
days in the following cases:  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  85    ◼ Serious and unexpected suspected adverse reactions, only if there is evidence to suggest 
a causal relationship between the drug and the AE 
◼ Findings from other studies, such as epidemiological studies, pooled analysis of multiple 
studies, or clinical studies that suggest a significant risk in humans exposed to the drug  
◼ Findings from animal or in vitro testing : Any finding from animal or in vitro testing , 
whether or not conducted by the Sponsor , that suggest a significant risk in humans 
exposed to the drug, such as reports of mutagenicity, teratogenicity, or carcinogenesis or 
reports of organ toxicity  
◼ Increased rate of occurrence of serious suspected adverse reactions. Any clinically 
important in crease in the rate of serious suspected adverse reactions over that listed in 
the protocol or investigator’s brochure  must also be reported  
The Sponsor or designee will notify the FDA and all participating Principal Investigators of any 
unexpected fatal or  life-threatening suspected adverse reaction as soon as possible but no later than 
7 calendar days after the initial receipt of the information. The investigators will follow their 
institutional policies of reporting safety information to the institutional  review board (IRB). They 
will provide copies of the correspondence with the ethics committee (EC) to the Sponsor or 
designee for filing.  
 
 
8.7 Pregnancy  
Sexually active men who have partners of childbearing potential and all females of childbearing 
potent ial must use an effective method of birth control (e.g., oral contraceptives, double -barrier 
methods, hormonal injectable, implanted contraceptives, or vasectomy) during the study and for 30 
days after the last dose of study drug is administered.  
 
Childbea ring Potential . Females of childbearing potential are female patients who are not 
surgically sterile (no history of bilateral tubal ligation, hysterectomy, or bilateral salpingo -
oophorectomy), are not postmenopausal (at least 1 year without menses), and ar e not otherwise 
sterile by medical evaluation. These patients must use an adequate form of birth control as 
determined by the investigator. Spermicidals are considered one component of a double -barrier 
method. Complete abstinence from sexual intercourse wi ll suffice without additional contraceptive 
measures. However, it is recommended that the Principal Investigator discuss all options with these 
female patients and instruct that if the patient becomes sexually active, she must use appropriate 
contraceptive  measures.  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  86     
Similarly all men who become sexually active during the study with a partner of childbearing 
potential must be instructed to use appropriate contraceptive measures.  
 
Sterile or Postmenopausal . Females who are surgically sterile or postmenopausa l will also be 
eligible for the study. Postmenopausal is defined as having had no menses for at least 12 months and 
having an FSH level above 35 IU/L for reproductive -age females. A surgically sterile status is 
defined as having a history of bilateral tuba l ligation, hysterectomy, or bilateral salpingo -
oophorectomy.  
 
Suspected Pregnancy . During the study, all females of childbearing potential will be instructed to 
contact the investigator immediately if they suspect they might be pregnant (e.g., late or mis sed 
menstrual period). Male patients will be instructed to contact the investigator if a sexual partner 
suspects she may be pregnant.  
 
If a patient or investigator suspects that the patient may be pregnant before study drug 
administration, the study drug m ust be withheld until the results of laboratory pregnancy testing are 
available. If pregnancy is confirmed, the patient must not receive the study drug and must be 
withdrawn from the study. The investigator must immediately notify the medical monitor of a 
pregnancy associated with study drug exposure and record the event on the Pregnancy Surveillance 
Form that will be provided to each site. Protocol -required procedures for study discontinuation 
must be performed on the patient unless contraindicated by preg nancy (e.g., x -ray studies). Other 
appropriate follow -up procedures should be considered if indicated.  
 
The investigator must follow up with a pregnant patient or the pregnant partner of any sexually 
active male patient every 4 weeks while the woman is pre gnant and every 4 weeks thereafter to 
follow perinatal and neonatal  outcome. The investigator must report follow -up information 
regarding the course of the pregnancy, including perinatal and neonatal outcome , on the appropriate 
Pregnancy Surveillance Form.  Infants who result from such pregnancies should be followed for a 
minimum of 8 weeks for safety assurances.  
 
Pregnancy Surveillance Forms will be submitted to the Westat R egulatory Affairs  Department via 
the SAE fax line. HHS  encourages the reporting of all in utero exposures to antiretroviral agents to 
the Antiretroviral Pregnancy Registry (telephone 800 -258-4263 or fax 800 -800-1052).  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  87     
9. Statistical Considerations  
 
9.1 General Methodology  
The data collected are intended primarily for clinical review and interpretation.  The analysis of study 
data will be primarily descriptive, with emphasis on tabular and graphical displays.  Descriptive 
statistics will be used to guide decisions as to the clinical relevance of fin dings.  Unless otherwise 
stated, p -values will be determined only if they appear to be warranted from the summary statistics.  
 
For continuous data, descriptive statistics will be presented as number of patients (n), mean, 
standard deviation, median, minimum , and maximum.  For categorical data, the frequency and 
percentage of patients in each category will be presented.  Percentages will be based on non -missing 
data unless otherwise specified.  
 
Data will be described and analyzed using the SAS System Version 9 .3 or later  (SAS Institute Inc., 
Cary, NC, SAS System).  Individual patient data will be presented in patient data listings.  
 
 
9.2 Populations for Analysis  
9.2.1  Efficacy Populations  
9.2.1.1  Intent -to-Treat Population  
The ITT population is defined as all pat ients enrolled  into the study.  Patient disposition will be 
based on the ITT population.  The ITT Analysis Population will be used for the primary analysis at 
Day 7. Patients with missing effectiveness data at Day 7 will have their effectiveness set to failure for 
all dichotomous effectiveness variables. This will be referred to as the MEF  analysis.  
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  88    9.2.1.2  Modified Intent -to-Treat Population  
The modified intent -to-treat ( mITT ) population is defined as all ITT patients who received at least 
one dose of study drug.  The mITT Analysis Population will be used for a supportive effectiveness 
analysis and will include all data without imputing values for missing data.  
 
 
9.2.2 Safety Population  
All patients who receive at least one partial dose of study drug will be included in the safety dataset 
for analysis (SAF) population.  Patients will be analyzed according to the treatment they actually 
received.  The safety population will be used for the safety analyses.  
 
 
9.3 Patient Disposition  
Study completion data will be summarized for all enrolled  patients.  The number and percent age of 
patients who complete treatment , discontinue study medication prematurely , or discontinue the 
study prematurely , will be tabulated.  The primary reason for premature discontinuation of study 
medication and/or discontinuation from study participation will be tabulated.  Any additional 
reason(s) for premature discontinuation of study medication will also be tabulated. A listing of all 
enrolled patients will be provided.  
 
 
9.4 Definition of Baseline  
For patients in Cohort 1 who were enrolled in the TMB -202 or TMB -301 studies , Baseline values 
for TMB -311 are defined as the values recorded for the Baseline visit in the previous  study. For 
patients in Cohort 1 who were not enrolled in the TMB -202 or TMB -301 studies , Baseline values for 
TMB -311 are  defined as the last values recorded prior to receiving the first dose of ibalizumab. For 
patients in Cohort 2, Baseline is defined as the Day 0 visit of TMB -311 (this study).  
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  89    9.5 Demographics and Baseline Char acteristics  
Descriptive statistics will be presented for demographic and other baseline characteristics for the 
ITT and mITT populations.  Medical history and  medication history findings will be listed and 
summarized.  
 
 
9.6 Exposure to Study Medication  
Dura tion of treatment will be presented for the mITT population.  
 
 
9.7 Safety Analyses  
The safety analyses will include descriptions of TEAEs, Class C events per the CDC Classification 
System for HIV Infection, clinical laboratory test results, physical examination findings, vital sign 
results, and ibalizumab  antibody levels (immunogenicity of ibalizumab ). 
 
 
9.7.1 Adverse Events  
The incidenc e (n and %) of AEs, SAEs , and early termination of study medication or study 
participation due to an AE will be presented. Additionally, AEs will be tabulated according to 
severity and relatedness categories as reported by the investigator.  AEs will be pre sented in tables 
organized alphabetically by Preferred Term within System Organ Class.  Each patient will be counted 
only once for each AE reporting level.  
 
 
9.7.2 Clinical Safety Laboratory Parameters  
Clinical laboratory parameters will be presented by vis it. Descriptive statistics will be used to 
summarize observed values by visit as well as the change from Baseline at each visit.  Clinical 
laboratory values outside the normal ranges will be flagged in patient data listings . Non-numeric data 
will be present ed in patient data listings, but will not be tabulated.  
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  90     
9.8 Efficacy  
The p rimary efficacy endpoint (Cohort 2 only) is the p roportion of patients achieving a ≥0.5 log 10 
decrease in viral load from Baseline  to Day 7 along with a 95% confidence interval  around the 
observed rate . 
 
Secondary effectiveness endpoints  (Cohort 2)  include : 
 
◼ Proportion of patients with HIV -1 RNA levels <50 copies/mL and <400 copies/mL at 
assessment time points  
◼ Mean change from Baseline in viral load at Day 7 and all assessment time points   
◼ Proportion of patients achieving a ≥0.5 log 10 and ≥1.0 log 10 decrease from Baseline in 
viral load at all assessment time points  
Exploratory statistical analyses will explore c hanges in HIV -1 drug sensitivity/susceptibility to 
determine relationships with protocol -defined virologic failure after ibalizumab  administration in 
combination with the OBR.   
 
 
10. Data Handling and Quality Assurance  
 
10.1  Electronic Case Report Forms  
An EDC will be used to capture data electronically for this trial, meaning that all data will be entered 
in the EDC system from source documents at the investigational site. Case report forms (CRFs) will 
be developed to be used as worksheets. Complet ion of these worksheets is optional.  
 
A patient  ID list will be maintained separately  from the research records and will not be recorded or 
stored with the CRFs.  
 
All data must be entered in English. The EDC system should always reflect the latest observat ions 
on the patients participating in the trial. Therefore, the data are to be entered into the EDC as soon 
as possible during or after the patient’s visit. To avoid inter -observer variability, every effort should 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  91    be made to ensure that the same individual  who made the initial baseline determinations completes 
all antiviral activity/safety evaluations. The clinical site  monitor will verify that all data entries in the 
EDC system are accurate and correct. If some assessments have not been done, or if certain  
information is not available, not applicable, or unknown, the investigator should indicate this in the 
EDC system. The investigator will be required to sign off on the clinical data.  
 
The Sponsor or designee will review the EDC system and evaluate the ent ries for completeness and 
consistency. The clinical site  monitor will compare the data captured in the EDC system with the 
source documents to ensure there are no discrepancies between critical data recorded in the EDC 
system and the source documents. All entries, corrections, and alterations are to be made by the 
responsible investigator or his/her designee. The clinical site  monitor cannot enter data in the EDC 
system. Once clinical data in the EDC system have been submitted , corrections to the data field s will 
be marked by an audit trail, meaning that the reason for the change, the name of the person who 
performed the change, and the time and date of the change will be logged. Roles and rights of the 
site personnel responsible for entering the clinical da ta into the EDC system will be determined in 
advance and documented on the appropriate form.  
 
If additional corrections are needed, the responsible clinical site  monitor or project data manager will 
raise a query in the EDC application. The appropriate inv estigational staff will answer queries sent to 
the investigator. This correspondence will be marked by an audit trail by the EDC application, 
meaning that the name of investigational staff  and the  time and date stamp are captured for each 
interaction/revis ion. 
 
 
10.2  Monitoring of the Study  
The purpose of clinical site monitoring is to ensure that the trial is conducted in an ethically sound 
and scientifically rigorous manner. Specifically, sites will be  carefully monitored by the Sponsor or 
designee to ens ure that (1) the rights and well -being of participants  are protected; (2) data are 
complete, accurate, and verifiable; and (3) the trial is conducted in compliance with the protocol,  
applicable government regulations (e.g., US FDA, Taiwan Food and Drug Adm inistration [TFDA ]), 
the ICH E6(R1): Guidelines for Good Clinical Practice, local IRB policies, and current standard 
operating procedures  at the sites ), and the Sponsor/Sponsor’s representative . 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  92    The clinical site monitor, as a representative of the Sponsor,  formally evaluates the accuracy and 
completeness of the data collected  and assesses compliance with the relevant regulations and 
policies. In doing so, the clinical site monitor will visit the Principal Investigator and study facility 
periodically , in addition to maintaining necessary telephone, email, or letter contact. The  clinical site  
monitor will maintain current personal knowledge of the study through observation, review of study 
records and source documentation, and discussion of the conduct  of the study with the Principal 
Investigator and staff.  
 
Each investigator is expected to make a reasonable effort to accommodate the clinical site monitor 
when site visits are necessary. Because this trial is utilizing an EDC system, the monitor will need to 
access the data entry computer and internet during the visit.  
 
 
10.3  Inspection of Records  
Principal Investigators and institutions involved in the study will permit trial -related monitoring, 
audits, IRB review, and regulatory inspection(s) by prov iding direct access to all study records. In the 
event of an audit, the Principal Investigator agrees to allow the Sponsor, representatives of the 
Sponsor, the US FDA, or other relevant regulatory authorities access to all study records.  
 
The Principal Investigator should immediately notify the Sponsor or designee of any audits 
scheduled by any regulatory authorities and promptly forward , to the Sponsor or designee , copies of 
any audit reports received.  
 
 
10.4  Study Record Retention  
Essential documents shou ld be retained for at least 2 years after the last approval of a marketing 
application in an ICH region (or longer if mandated by the local IRB). Moreover, they should be 
retained until there are no pending or contemplated marketing applications in an ICH region or at 
least 2 years have elapsed since the formal discontinuation of clinical development of the 
investigational product. However, if required by the applicable regulatory requirements or by an 
agreement with the Sponsor , these documents should be r etained for a longer period . It is the 
responsibility of the Sponsor or designee to inform the Principal Investigator or institution as to 
when these documents no longer need to be retained.  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  93     
 
11. Administrative Considerations  
 
The following administrative items are meant to guide the Principal Investigator in the conduct of 
the trial but may be changed based on industry and government standard operating procedures, 
working practice documents, or guidelines. Any changes in trial procedures will be reported to the 
IRB, but will not necessarily result in a protocol amendment.  
 
 
11.1  Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner 
designed to maintain patient confi dentiality. All records will be kept in a secure storage area with 
limited access. Clinical information will not be released without the written permission of the patient 
(or the patient’s guardian), except as necessary for monitoring and auditing by the S ponsor, its 
designee, the US FDA or applicable regulatory authorities, or the IRB.  
 
The Principal Investigator and all employees and coworkers involved with this study may not 
disclose or use for any purpose , other than performance of the study, any data, record, or other 
unpublished confidential information disclosed to those individuals for the purpose of the study. 
Prior written agreement from the Sponsor or designee must be obtained for the disclosure of any 
said confidential information to other partie s. 
 
 
11.2  Institutional Review Board or Independent Ethics 
Committee Approval  
Federal regulations and the ICH guidelines require that approval be obtained from an IRB/EC 
before participation of human patients in research studies. Before the study onset, the protocol, 
informed consent, advertisements to be used for patient recruitmen t, and any other written 
information regarding this study to be provided to the patient or the patient’s legal guardian must be 
approved by the IRB/EC. Documentation of all IRB/EC approvals and of the IRB/EC compliance 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  94    with ICH E6(R1), US FDA, TFDA , and ot her applicable regulatory authorities will be maintained by 
the site and available for review by the Sponsor or designee.  
 
The Principal Investigator is responsible for obtaining continued review of the clinical research at 
intervals specified by the IRB, but not exceeding 1 year. The Principal Investigator must supply the 
Sponsor or designee with written documentation of continued review of the clinical research.  
 
 
11.3  Modification of the Protocol  
This protocol will be implemented as approved by the IRB , and no changes will be implemented 
prior to IRB approval except those necessary to remove an apparent immediate hazard to the 
patient. Amendments to the protocol must be approved by the IRB prior to implementation.  
 
 
11.4  Informed Consent  
A signed informed  consent form, in compliance with Title 21 of the US Code of Federal 
Regulations (CFR) Part 50 and in accord ance with  other regulations for non -US sites, will be 
obtained from each patient before any study -related procedures are performed  and any personal 
information is collected . An informed consent template may be provided to investigative sites by the 
Sponsor or designee. The consent must be reviewed by the Sponsor or designee  before IRB 
submission i f the site proposes or makes any institution -specific modifications to study -related 
procedures, the risk language , or any other significant changes that would alter the information 
relayed . Once reviewed, the consent will be submitted by the Principal Investigator to his /her IRB 
for review and approval before the start of the study. If the informed consent form is revised during 
the course of the study, all active participating patients must sign the revised IRB -approved consent 
form.  
 
Before enrollment, eac h prospective patient will be given a full explanation of the study and allowed 
to read the approved informed consent form. The information given should  be in a language or 
manner that is easily understandable to the participant or legal guardian. Once the  Principal 
Investigator is assured that the patient/legal guardian understands the implications of participating 
in the study and ha s been given the proper time to consider whether to participate or not, the 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  95    patient/legal guardian will be asked to give con sent to participate in the study by signing the 
informed consent form. The Principal Investigator will also sign the form at that time.  
 
The Principal Investigator will provide a copy of the signed informed consent form to the patient 
and/or legal guardian . The original form will be maintained in the patient’s medical records at the 
site. 
 
 
11.5  Protocol Violations and Deviations  
A deviation from the protocol is an unintended and/or unanticipated departure from the procedures 
and/or processes that were appr oved by the Sponsor and the IRB , and that were agreed to by the 
Principal Investigator. Deviations usually have an impact on individual patients or a small group of 
patients and do not involve inclusion/exclusion or primary endpoint criteria. A protocol vi olation 
occurs when (1) there is non -adherence to the protocol that results in significant additional risk to 
the patient, ( 2) the patient or Principal Investigator has failed to adhere to significant protocol 
requirements  (e.g., inclusion/exclusion criter ia), or (3) there is non -adherence to FDA regulations 
and/or ICH E6(R1) guidelines.  
 
For this protocol, violations will be defined as exceptions to the inclusion or exclusion criteria, 
situations where a patient is required to withdraw but the investigator  believes the patient should 
remain in the study, and the use of an excluded concomitant medication. All other departures from 
the protocol (e.g., missed visit windows, laboratory samples not collected on the required day) will 
be documented as protocol de viations. The Principal Investigator or designee must document and 
explain any protocol deviation or violation in the patient’s source documentation. The investigator 
should notify the IRB of all protocol violations and deviations per local institutional policy. Protocol 
deviations and violations will be documented by the responsible clinical site monitor during 
monitoring visits, and those observations will be reviewed with the investig ator. 
 
The Principal Investigator may implement a change from the protocol without prior Sponsor and 
IRB approv al only to eliminate an immediate hazard to a patient. The implemented change should 
be submitted to the IRB for review as soon as possible.  
 
If the investigator believes that an exception to the protocol is justified for an individual patient, the 
investigator may present the facts and rationale to the medical monitor and request a one -time 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  96    exception. This request will be submitted in writing on a  protocol inquiry form, which will be faxed 
to the medical monitor for review and disposition. The medical monitor will then fax the decision to 
the investigator  regarding approval or denial of the request.  This written documentation must be 
filed in the i nvestigator’s study file.  
 
This process will apply if the investigator believes that a patient should receive an excluded 
concomitant medication and remain in the study, or if the investigator believes that a patient should 
remain in the study when the pro tocol dictates that the patient should be discontinued. The 
implemented change should be submitted to the IRB for review as soon as possible. However, it is 
the policy of the Sponsor that there will be no exceptions granted concerning the inclusion and 
exclusion criteria.  
 
 
11.6  Study Reporting Requirements  
By participating in this study, the Principal Investigator agrees to submit reports of AEs according to 
the timeline and method outlined in the protocol. In addition, the Principal Investigator agrees to 
submit periodic reports to his/her IRB as appropriate.  
 
 
11.7  Financial Disclosure and Obligations  
Principal Investigators and subinvestigators are required to provide financial disclosure information 
to allow the Sponsor or designee to submit the complete and accurate certification or disclosure 
statements required under Title 21 CFR 54. In addition, t he Principal Investigator and 
subinvestigators must provide the Sponsor or designee with a commitment to update this 
information promptly, if any relevant changes occur during the course of the investigation and for 1 
year following the completion of the s tudy.  
 
The Sponsor or designee is not financially responsible for further testing/treatment of any medical 
condition that may be detected during the Screening process. In addition, in the absence of specific 
arrangements, the Sponsor or designee is not fin ancially responsible for treatment of the patient’s 
disease.  
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  97    11.8  Investigator Documentation  
Before beginning the study, the Principal Investigator will be asked to comply with ICH E6(R1) 8.2, 
Title 21 CFR , and other applicable regulatory requirements by providing the essential documents to 
the Sponsor or designee, which include but are not limited to the following:  
 
◼ An original Investigator -signed investigator agreement page of the protocol  
◼ Documentation of  IRB approval of the protocol and informed consent  
◼ The IRB -approved informed consent, samples of site advertisements for recruitment 
for this study, and any other written information regarding this study that is to be 
provided to the patient or legal guard ians. 
◼ A Form FDA 1572, fully executed, and all updates on a new fully executed Form FDA 
1572. 
◼ Curricula vitae for the Principal Investigator and each subinvestigator listed on Form 
FDA 1572. A copy of the current license must be provided. The curricula vit ae must be 
signed and dated by the Principal Investigators and subinvestigators within 1 year before 
study start -up to indicate that the documents are accurate and current . 
◼ Completed financial disclosure forms to allow the Sponsor or designee to submit 
complete and accurate certification or disclosure statements required under Title 21 
CFR 54. In addition, the investigators must provide to the Sponsor or designee with a 
commitment to update this information promptly if any relevant changes occur during 
the course of the investigation and for 1 year following the completion of the study 
(Section 11.7 ). 
◼ Laboratory certifications and normal ranges for any local laboratories used by the site, in 
accordance with Title  42 CFR 493 . 
 
11.9  Study Conduct  
The Principal Investigator agrees that the study will be conducted according to the principles of ICH 
E6(R1), the principles of the World Medical Association Declaration of Helsinki, and regulatory 
requirements of the US FD A and TFDA. The Principal Investigator will conduct all aspects of this 
study in accordance with all national, state, and local laws or regulations.  
 
 
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  98    11.10  Publications  
Following completion of the study, the data may be considered for reporting at a scientific meeting 
or for publication in a scientific journal. In these cases, the Sponsor or designee will be responsible 
for these activities and will work with the investigators to determine how the manuscript is written 
and edited, the number and order  of authors, the publication to which it will be submitted, and 
other related issues. The Sponsor has final approval authority over all such issues.  
 
Data are the property of the Sponsor and cannot be published without prior authorization from the 
Sponsor.  
 
A description of this clinical trial (study ) will be available on  http://clinicaltrials.gov , as required by 
US law. 
 
 
  
TAIMED BIOLOGICS, INC.  CONFIDENTIAL  
PROTOCOL: TMB -311 DATE: 11 DECEMBER  2017 
 
 
    
Use or disclosure of data contained on this page is subject  
to the restriction on the title page of this proposal or quotation.  99    References  
 
 
1 Gardner, E.M., McLees, M.P., Steiner, J.F., Del Rio, C., and Burman, W.J . (2011). The 
spectrum of engagement in HIV care and its relevance to test-and-treat strategies for 
prevention of HIV infection. Clinical Infectious Diseases , 52(6): 793-800.  
2 U.S. Centers for Disease Control and Prevention. (2011).  HIV prevalence estimates —United 
States . Morbidity and Mortality Weekly Report, 60(47) :1618-1623. 
3 Panel on Antiretroviral Guidelines for Adults and Adolescents. (2014). Guidelines for the use of 
antiretroviral agents in HIV -1-infected adults and adolescents. Washington, DC: U.S. Department of 
Health and Human Services.  
4 Schwartzberg , L.S., Stepanski , E.J., Fortner , B.V., and Houts , A.C. (2008). Retrospective chart 
review of severe infusion reactions  with rituximab, cetuximab, and bevacizumab in community 
oncology practices: Assessment of clinical consequences. Support ive Cancer  Care, 16:393 -398. 
5 Dillman , R.O. (1999). Infusion reactions associated with the therapeutic use of monoclonal 
antibodies in the treatment of malignancy. Cancer and Metastasis Reviews , 18:465 -471. 
6 Dalakas , M.C. (2004). The use of intravenous immunoglobulin in the treatment of autoimmune 
neuromus cular disease: Evidence -based indications and safety profile. Pharmacology and 
Therapeutics , 102:177 -193. 
7 Schwartzberg , L.S., Stepanski , E.J., Fortner , B.V., and Houts , A.C. (2008). Retrospective chart 
review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community 
oncology practices: Assessment of clinical consequences. Support ive Cancer  Care, 16:393 -398. 
 